Duodenal hypoxia-inducible factor-2 alpha (HIF-2α) and iron-related proteins in alcoholic liver disease by Mathuravalli, S
1 
 
 
DUODENAL HYPOXIA-INDUCIBLE FACTOR-2 ALPHA (HIF-2α) AND 
IRON-RELATED PROTEINS IN ALCOHOLIC LIVER DISEASE 
 
DISSERTATION  
Submitted to  
THE TAMILNADU DR.MGR MEDICAL UNIVERSITY  
In partial fulfillment for the degree  
   
DOCTOR OF MEDICINE  
IN  
BIOCHEMISTRY - BRANCH XIII 
MAY 2018  
 
 
 
2 
 
DUODENAL HYPOXIA-INDUCIBLE FACTOR-2 ALPHA (HIF-2α) AND 
IRON-RELATED PROTEINS IN ALCOHOLIC LIVER DISEASE 
DISSERTATION  
Submitted to  
THE TAMILNADU DR.MGR MEDICAL UNIVERSITY  
In partial fulfillment for the degree    
DOCTOR OF MEDICINE  
IN  
BIOCHEMISTRY - BRANCH XIII 
MAY 2018  
                                           DEPARTMENT OF BIOCHEMISTRY  
CHRISTIAN MEDICAL COLLEGE  
VELLORE- 632002, INDIA 
3 
 
  
CERTIFICATE 
This is to certify that the study titled "DUODENAL HYPOXIA-INDUCIBLE FACTOR - 2 
ALPHA (HIF-2α) AND IRON-RELATED PROTEINS IN ALCOHOLIC LIVER 
DISEASE" is the bonafide work of Dr.S.Mathuravalli, who conducted it under the guidance and 
supervision of Dr. Molly Jacob, Professor of Biochemistry, Christian Medical College, Vellore. 
The work in this dissertation has not been submitted to any other university for the award of a 
degree.  
  
Dr. Molly Jacob,  
Professor and Head,  
Department of Biochemistry,  
Christian Medical College,  
Vellore.  
  
Dr. Anna B. Pulimood,  
Principal,  
Christian Medical College,  
Vellore. 
4 
 
DECLARATION 
I hereby declare that the investigations, which form the subject matter of this study, were 
conducted by me under the supervision of Dr.Molly Jacob, Professor of Biochemistry, Christian 
Medical College, Vellore.  
  
  
Dr.S.Mathuravalli, 
PG Registrar,  
Department of Biochemistry,  
Christian Medical College,  
Vellore.  
 
 
 
 
 
 
 
5 
 
PLAGIARISM CHECK 
  
  
  
  
  
 
 
6 
 
ACKNOWLEDGEMENTS 
I take this opportunity to express my thanks and profound gratitude to the following people for 
their support and encouragement, which made this work possible.  
Dr. Molly Jacob, my guide and mentor. I am grateful for her patience, valuable time, guidance, 
encouragement, care and support. I am indebted to her for what she has been to me.  
Dr. Joe Varghese, my co-guide for his guidance, encouragement, technical support and valuable 
opinions.  
Dr.A J Joseph, Professor and Head, Department of Gastroenterology, CMC, Vellore, for his 
guidance, support and help in recruitment of patients. 
Dr. Eapen CE, Professor, Department of Hepatology, CMC, Vellore, for help in recruitment of 
patients. 
Dr. Premila Abraham, Dr.Prakash SS, Dr.Anand R, Dr.Muthuraman N for their encouragement 
and support.  
Dr.Victoria Job, Dr.Geethanjali F S and Mr. Joseph Dian Bondu, Department of Clinical 
Biochemistry for their help and support.  
Dr. Thambu David and CEU team for their time, dedication and patience to teach us the usage of 
reference manager and data entry software and the structured epidemiology workshop for thesis 
completion. 
Dr.Jagadish R, Dr.Arthi T S, Dr.Padmanaban V, Dr. Rosa Mariam Mathew, Dr.Gopinath M,  
7 
 
Dr. Peter Monica, Dr.Jeninth Mohan for their cheerful presence and support.  
Mr. Jithu V James, for technical support and help in processing of samples. 
Mr. Sridhar R, Mr. Issac Newton A, Mr. Lalu U, Mr. Kumerasan R for their assistance and 
support  
Mrs. Punitha Martin for secretarial help.  
I thank my husband, parents, parents-in-law and my children for always being there to support 
me.  
I gratefully acknowledge CMC’s Fluid Research Funds for financial support for this study (IRB 
Min No. 9816 dated 07.01.16).  
 
  
  
  
  
  
  
  
 
8 
 
TABLE OF CONTENTS 
Chapter No.      Title Page No.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
 
 
 
 
 
 
 
 
 
 
 
 Abstract                                                                                                                             
 Review of literature  
 The study  
 Materials  
 Methods  
 Results 
 Discussion  
 Conclusion 
 Limitations of the study 
 Bibliography 
 Appendices 
 Appendix I- Letter of approval from the  
 Institutional Review Board (IRB)  
 Appendix II -Information sheet and consent form  
 Appendix III- Proforma for study   
 Appendix IV- MIQE checklist  
 Appendix  V- Master data sheet 
9 
 
11 
 
35 
 
37 
 
39 
 
68 
 
90 
 
99 
 
99 
 
100 
 
 
 
113 
 
 
 
117 
 
132 
 
133 
 
139 
 
  
 
 
 
 
 
9 
 
ABSTRACT 
Background to the study 
Alcoholic liver disease (ALD) is often associated with dysregulation of iron homeostasis. 
Previous work from the investigators’ group has shown that expression of proteins involved in 
duodenal iron absorption were down-regulated in patients with ALD. Several factors are known 
to regulate expression of these duodenal proteins (which include divalent metal transporter 1 
[DMT-1], duodenal cytochrome b [Dcytb] and ferroportin). Hepcidin is one such factor. Serum 
hepcidin levels were deceased in these subjects and, hence, this did not explain the decreased 
expression of the duodenal proteins. Hypoxia-inducible factor-2α (HIF-2α) in the duodenum is 
another such regulator, which is known to induce the transcription of these duodenal proteins. 
Studies done in mice have shown that chronic alcohol ingestion decreased intestinal HIF-2α 
levels. However, it is not known whether HIF-2α expression is altered in patients with ALD.  
Aim 
To determine protein expression levels of HIF-2α and gene expression levels of divalent metal 
transporter 1 (DMT-1), ferroportin and duodenal cytochrome b (Dcytb) in duodenal mucosal 
samples obtained from patients with ALD and in control subjects. 
Methods 
Eighteen patients with ALD and 18 control subjects were recruited for the study, after obtaining 
informed consent. Blood and duodenal mucosal samples were collected from these patients, each 
of whom underwent a medically-indicated upper gastrointestinal endoscopy. Blood samples were 
used for estimation of hematological parameters, liver function tests, high-sensitivity C-reactive 
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protein (hs-CRP) and markers of iron status. The duodenal mucosal samples were used for 
western blot analysis to determine protein levels of HIF-2α and for quantitative PCR to 
determine mRNA expression of DMT-1, Dcytb and ferroportin.  
Results 
Hemoglobin and total iron-binding capacity (TIBC) were significantly lower in patients with 
ALD than in control subjects. Serum levels of ferritin and hs-CRP and transferrin saturation were 
significantly higher in patients with ALD than in control subjects. Protein levels of HIF-2α and 
mRNA expression of DMT-1, Dcytb and ferroportin in duodenal mucosal samples were not 
significantly different in the two groups. HIF-2α did not correlate with the mRNA expression of 
any of the duodenal proteins involved in iron absorption. 
Conclusion 
The results of this study showed that patients with ALD were anemic and showed evidence of 
systemic inflammation. HIF-2α was not found to be altered in patients with ALD. However, the 
sample size of this study was small. An adequate sample size needs to be studied to confirm 
these findings. 
Keywords: Alcoholic liver disease, duodenum, HIF-2α, iron  
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REVIEW OF LITERATURE  
INTRODUCTION 
Excessive alcohol consumption is a global health problem, with enormous social, economic, and 
clinical consequences. Alcohol consumption accounts for nearly 5.9% of all global deaths 
(World Health Organization and Management of Substance Abuse Unit, 2014).  Excessive 
drinking over many years damages nearly all organs in the body, of which the liver sustains the 
earliest and greatest injury. This is because the liver is the primary site of metabolism of ethanol. 
Alcoholic liver disease (ALD) is the most important cause of death due to alcohol use in adults 
(Rehm et al., 2013). 
ALCOHOLIC LIVER DISEASE (ALD) 
Heavy alcohol consumption produces a spectrum of pathological changes in the liver. The most 
characteristic of these are fatty liver (steatosis), hepatitis, fibrosis/cirrhosis and hepatocellular 
carcinoma. These pathological hallmarks of ALD – steatosis, inflammation and fibrosis - are the 
result of interrelated and consecutive events that occur due to continuous alcohol exposure 
(Stickel et al., 2017). 
The pathogenesis of alcoholic liver injury is unclear. Alcohol is metabolized in the liver mainly 
by aldehyde dehydrogenase in the cytosol. Other minor pathways are those by CYP2E1 in 
endoplasmic reticulum and catalase in peroxisomes. Acetaldehyde produced by the reaction is 
highly reactive and toxic to the hepatocytes (Konishi and Ishii, 2007). Reactive oxygen species 
(ROS) and lipid peroxidation products along with inflammation in chronic alcohol intake may 
cause liver injury (Magdaleno et al., 2017). 
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Figure 2.1. Spectrum of pathological changes in ALD 
 
Source: Stickel et al (2017). Pathophysiology and Management of Alcoholic Liver Disease: 
Update 2016. Gut Liver 11, 173–188 
 
Role of iron in pathogenesis of ALD 
Most heavy alcohol consumers do not progress beyond steatosis of the liver, which suggests that 
other factors contribute to progression of disease in ALD. One such factor, which has been 
postulated to promote disease progression in ALD, is iron (Magdaleno et al., 2017). 
Hepatic iron overload is seen in nearly 50% of patients with ALD (Basaranoglu et al., 2013; 
Milic et al., 2016). Chronic alcohol consumption in moderate to excessive amounts is associated 
with elevation of levels of serum ferritin and transferrin saturation, and is suggestive of increased 
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hepatic iron stores (Milic et al., 2016). Excess iron and alcohol individually cause oxidative 
stress and lipid peroxidation. Hence, alcohol-induced iron overload enhances the production of 
free radicals and proinflammatory cytokines. The cumulative effects of iron and ethanol thus 
cause liver cell damage and exacerbate liver injury in patients with ALD (Mueller and Rausch, 
2015). 
IRON  
Iron is a transition metal and is an essential micronutrient. It is indispensable for living 
organisms, as it is a cofactor for several hemoproteins and non-heme iron-containing proteins 
(Rodwell et al., 2015). Functions of hemoproteins include oxygen transport (hemoglobin), 
oxygen storage (myoglobin) and cellular respiration and electron transport (cytochromes). Non-
heme iron-containing proteins are important for DNA synthesis, cell proliferation and 
differentiation (ribonucleotide reductase)  (Pantopoulos et al., 2012). 
Iron can exist in two redox states (Fe⁺⁺ and  Fe⁺⁺⁺). This property of iron is useful in biochemical 
reactions, to donate or accept electrons (Evstatiev and Gasche, 2012). This property also makes it 
toxic if iron is present in its free form. Free iron has the ability to catalyze the formation of 
harmful oxygen free radicals, via the Fenton reaction and Haber Weiss reaction, which may 
cause cellular and tissue damage (Haber and Weiss, 1934). Hence, in biological systems, iron is 
always protein-bound to minimize such free radical-mediated damage. 
Approximately 3- 4 g of iron is found in an average adult human. Iron present in the human body 
is derived from absorption from the gut or from recycling of iron in macrophages (from heme in 
senescent RBCs)  (Rodwell et al., 2015). Most of the body’s requirements for iron are met by 
recycling of iron in the macrophages. Loss of 1 -2 mg iron/day occurs  through desquamation of 
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intestinal epithelial cells (Green et al., 1968). In females, the loss is higher due to menstruation.  
Iron losses are balanced by absorption of dietary iron, which occurs mainly in the proximal 
duodenum. These losses are not regulated. Hence, regulation of the iron content of the body 
occurs mainly at the level of absorption (Gulec et al., 2014a). 
Dietary iron and its absorption  
The major form of iron in the diet is non-heme iron; heme iron is found in small quantities and is 
absorbed better. This is because, absorption of non-heme iron is affected by the iron status of an 
individual and other dietary factors, while absorption of heme iron is less affected by such 
factors (Hallberg, 1983). 
Absorption of non-heme iron 
The main site of iron absorption is the proximal duodenum (Muir and Hopfer, 1985). Proteins 
involved in the uptake of iron from the food are present in the brush border membrane of the 
enterocyte.  
Divalent metal transporter1 (DMT-1) 
Non-heme iron is taken up mainly by the divalent metal transporter (DMT-1) located in the 
brush border of enterocytes. This transmembrane protein is also known as divalent cation 
transporter (DCT) and natural resistance associated macrophage protein 2 (NRAMP2). In 
humans, this protein is encoded by the SLC11A2 gene. DMT-1 also transports other divalent 
metal ions such as manganese, cobalt, copper and zinc, apart from iron. This transporter is active 
in an environment with a low pH, such as the duodenum, as it requires co-transport of protons 
(Gunshin et al., 1997). Iron found in the ferric form in the intestinal lumen has to be converted to 
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its ferrous form for absorption to occur. The conversion of ferric to ferrous form is brought about 
by the presence of ascorbate in the lumen of the gut or by membrane-bound ferrireductases 
(Hurrell and Egli, 2010). 
Duodenal cytochrome b (Dcytb) 
Ferric iron in the intestinal lumen is reduced to its ferrous form by the action of a ferrireductase, 
duodenal cytochrome b (Dcytb), which is found on the apical surface of enterocytes. This is a 
plasma membrane di-heme protein, first isolated from the duodenal mucosa of mice (McKie et 
al., 2001). This ferrireductase is more important in humans and other scorbutic species, which 
cannot produce ascorbic acid in vivo. However, in mouse models in which this protein was 
knocked out,  intestinal iron absorption was not found to be affected, suggesting that Dcytb may 
not be the only ferrireductase in the intestine (McKie, 2008). 
Ferroportin 
Iron that enters the enterocyte can be either stored as ferritin or exported to the plasma. 
Ferroportin is a transmembrane protein expressed on basolateral membrane of enterocytes. It is 
also known as iron regulated transporter 1 (IREG1), membrane transport protein (MTP) and 
SLC40A1. It is the only known iron exporter in mammalian cells (Donovan et al., 2005). Unlike 
DMT-1, it is selective for iron. 
Hephaestin 
Hephaestin is a membrane-bound homolog of ceruloplasmin, which is a serum multi-copper 
oxidase. It oxidizes the ferrous form of iron to its ferric form, when it is released from ferroportin 
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(Vulpe et al., 1999). The ferric form of iron gets incorporated into transferrin, which is the carrier 
protein for iron in blood.   
Absorption of heme iron 
Heme iron has a higher bioavailability than non-heme iron. However, the mechanism by which 
heme is absorbed is not totally clear. Proposed mechanisms involved in the absorption of heme 
iron include receptor- mediated endocytosis or a heme carrier protein (PCFT/HCP1-) which 
transports heme iron from the lumen into the cytoplasm of the enterocyte. Apart from heme 
transport, the PCFT/HCP1 transporter has also been shown to be a folate/proton symporter (West 
and Oates, 2008).  Heme is catabolized in the enterocytes by heme oxygenase 1 and 2, which 
release inorganic iron (Ryter et al., 2006). In spite of higher bioavailability, the absorption of 
heme iron cannot be upregulated to the same extent as non-heme iron, as seen in iron deficiency 
states (West and Oates, 2008). 
Figure 2.2 shows the process of intestinal iron absorption.  
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Figure 2.2. Intestinal iron absorption       
 
Source: Donovan et al (2006). The ins and outs of iron homeostasis. Physiol. Bethesda Md 21, 
115–123. 
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Iron in circulation  
Iron in circulation is bound to transferrin, a glycoprotein synthesized by the liver. It has two 
high- affinity iron-binding sites. When both sites are occupied by iron, it is referred to as 
holotransferrin. Under normal circumstances, transferrin is not fully saturated. Only 30-40% of 
its sites are iron-bound (transferrin saturation). In case of iron deficiency, the transferrin 
saturation drops to <16%; in iron overloaded states, the saturation is > 45% (Rodwell et al., 
2015). When transferrin saturation exceeds 60%, non-transferrin bound iron (NTBI) accumulates 
in the circulation (Hentze et al., 2010).  
Cellular iron uptake 
Under physiological conditions, most cells take up transferrin-bound iron from the circulation. 
Diferric transferrin binds to transferrin receptor 1 (TfR1) on the surface of cells.  Cellular uptake 
is facilitated by receptor-mediated endocytosis. When the pH of the endocytic vesicle is 5.5 or 
less, iron dissociates from the transferrin receptor complex, but apotransferrin remains bound to 
the receptor (Dautry-Varsat et al., 1983). Iron, which is in the ferric form is reduced to its ferrous 
form by endosomal reductase Steap 3 (six-transmembrane epithelial antigen of the prostate 3) 
(Ohgami et al., 2005). From the endosome, ferrous iron is transported through DMT-1 to the 
cytoplasm. The apotransferrin receptor complex is recycled to the cell surface. Apotransferrin 
then detaches from the receptor, when it encounters the more neutral pH of blood, thus 
completing the transferrin cycle. There are two types of transferrin receptors TfR1 and TfR2. 
TfR1 is found on the surface of most cells. TfR2 is found in hepatocytes and small intestinal 
crypt cells. TfR2 has a lower affinity for holotransferrin than TfR1. It functions as a sensor of 
iron levels. (Rodwell et al., 2015). 
19 
 
Non-transferrin-bound iron (NTBI) 
Uptake of NTBI is relevant in iron-overloaded conditions, such as like hereditary 
hemochromatosis and thalassemia. Such uptake by tissues such as the liver, heart and pancreas 
may help to clear potentially toxic levels of iron before damage due to iron catalysed-free 
radicals can accumulate (Lane and Lawen, 2008). Though the exact route of uptake of NTBI 
remains unclear, mechanistically it is thought to involve reduction of ferric iron to its ferrous 
form and import of the ferrous form into the cell through transporters such as DMT-1 or 
ZRT/IRT like proteins (ZIPs) , ZIP14 or ZIP 18 (Lane et al., 2015). 
Figure 2.3 illustrates the steps involved in cellular uptake of transferrin-bound and non-
transferrin-bound iron. 
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Figure 2.3. Cellular iron uptake 
  
Source: Lane et al (2015). Cellular iron uptake, trafficking and metabolism: Key molecules and 
mechanisms and their roles in disease. Biochim. Biophys. Acta BBA - Mol. Cell Res. 1853, 
1130–1144 
 
Cellular iron storage 
Iron in excess of a cell’s requirements is converted to an inert form to prevent cell damage due to 
production of reactive oxygen species. In non-erythroid cells, about 70 - 80% of iron taken up is 
incorporated into ferritin (Arosio and Levi, 2010). Ferritin has dual functions of iron storage and 
iron detoxification, by sequestering the iron (Harrison and Arosio, 1996). Mammalian ferritin 
consists of a multimeric protein shell, with 24 light and heavy chain subunits. The ferritin core 
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can accommodate about 4500 iron atoms in the form of ferric hydroxide. Each heavy subunit has 
a catalytic site that oxidizes two ferrous atoms (Liu and Theil, 2005). When cellular iron levels 
are low, iron is released from ferritin. 
Serum ferritin  
Apart from the cytosol and mitochondria, ferritin is also found in blood. Serum ferritin is 
considered to be a marker of body iron stores. It mainly consists of light chains; its core is 
relatively iron-poor, when compared with cellular ferritin (Evstatiev and Gasche, 2012). The 
primary source of serum ferritin is from macrophages (Cohen et al., 2010). Its exact function is 
not clear. Ferritin is also an acute phase protein, which increases in response to acute and chronic 
inflammation (Kell and Pretorius, 2014).  
IRON HOMEOSTASIS 
Systemic iron homeostasis 
The cell types involved in iron homeostasis include the following:  
1. Duodenal enterocytes, which absorbs dietary iron 
2. Macrophages, which recycle iron from phagocytosed erythrocytes and other cells  
3. Hepatocytes, which store iron and release it when required (Ganz, 2013) 
The most important regulated step in all these cells is the transfer of iron from these cells into the 
plasma. This step is regulated by hepcidin, a hormone produced by hepatocytes. 
Role of hepcidin 
Hepcidin was originally identified as a liver-expressed antimicrobial peptide (LEAP1), with 
antimicrobial activity against many bacterial and fungal species (Krause et al., 2000). It is 
encoded by the HAMP gene, located on the long arm of chromosome19. It is synthesized as a 
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biologically inactive 84-amino acid pre-proprotein; it is made up of a signal peptide, a pro-region 
and an active 25-amino acids sequence. It is proteolytically cleaved by the prohormone 
convertase, furin, resulting in the release of biologically active hepcidin (Valore and Ganz, 
2008). It is synthesized and secreted by hepatocytes, and circulates in the plasma; it binds weakly 
to albumin and α2-macroglobulin (Peslova et al., 2009). 
Hepcidin is mainly expressed in the liver. However, its expression has also been detected in 
macrophages, pancreatic beta cells, adipocytes, lungs and kidney (Kulaksiz et al., 2008; Nguyen 
et al., 2006). 
Hepcidin acts as a negative regulator of iron stores. Its production by the liver is induced in 
response to increased iron levels (Ganz, 2011). It acts at the site of iron absorption, storage and 
recycling and cause a decrease in release of iron into the plasma from the enterocyte, hepatocyte 
and macrophages (Rishi et al., 2015). It does so by binding and inducing the internalization and 
degradation of ferroportin, which is the only known iron exporter (Nemeth et al., 2004b). 
Regulation of hepcidin 
Hepcidin is regulated at a transcriptional level. Its expression is influenced by iron levels in the 
body, inflammation, erythropoietic activity and hypoxia (Ganz, 2013). Iron overload and 
inflammation up regulate hepcidin expression; iron deficiency, hypoxia and erythropoietic 
activity decrease it (Silva and Faustino, 2015). 
Cellular iron homeostasis 
Cellular iron homeostasis is maintained by regulation of the proteins involved in iron uptake, 
storage and release. These regulatory mechanisms occur at a post-transcriptional level. The IRE-
IRP  system is responsible for this regulation (Rouault, 2006).  
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Iron-responsive element and iron-regulatory proteins (IRE-IRP system) 
In iron-depleted cells, IRPs are induced. They bind to IREs in the 5’ or 3’ untranslated regions 
(UTR) in the mRNA for proteins involved in iron metabolism. Binding of the IRP to the 5’ UTR 
of the mRNA for ferritin, ferroportin, aminolevulinic acid synthase and hypoxia-inducible factor- 
2 alpha (HIF- 2α) suppress their translation. Binding of the IRP to the 3’UTR of mRNA for 
transferrin and DMT-1 results in increased stability of the mRNA (against nuclease attack) 
(Hentze et al., 2010). In iron-replete conditions, IRP1 acquires an iron sulphur cluster and loses 
its ability to bind to the IRE;  it then functions as a cytosolic aconitase (Lane et al., 2015). IRP2 
undergoes ubiquitination by FBXL 5 (F-box and leucine rich repeat protein 5) and proteasomal 
degradation in iron-replete cells (Guo et al., 1995). Hence, when iron levels increase, IRPs are 
not able to bind to the IREs, thus limiting acquisition of iron by cells.  
Figure 2.4 depicts how the IRE IRP system operates to regulate intracellular iron levels, in iron-
depleted and iron-replete conditions.  
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Figure 2.4. Regulation of intracellular iron levels by the IRE-IRP system 
 
 
Source: Anderson et al (2012). Mammalian iron metabolism and its control by iron regulatory 
proteins. Biochim. Biophys. Acta BBA - Mol. Cell Res., Cell Biology of Metals 1823, 1468–
1483. 
 
The gut in iron homeostasis 
No regulated mechanisms exist in humans to excrete iron.  Body iron levels are mainly 
controlled by modifying rates of absorption of iron in the proximal small intestine. The 
mechanisms that regulate iron absorption allow for appropriate increases or decreases in 
absorption, in accordance with physiological requirements.  Thus, absorption of iron is increased 
when body iron stores are low, when erythropoietic demand for iron is high, in chronic hypoxia, 
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and in pregnancy. Absorption of iron decreases when body iron stores are high and during 
infection/ inflammation. Intestinal iron absorption is regulated by systemic as well as cellular 
mechanisms to maintain adequate iron levels in the body. (Gulec et al., 2014b). 
Systemic regulation of iron absorption 
Duodenal enterocytes are an important target of hepcidin (Rivera et al., 2005). An inverse 
relationship exists between hepcidin levels and expression of duodenal proteins involved in iron 
absorption (Frazer et al., 2002). This effect of hepcidin is mediated by its interaction with 
ferroportin on the basolateral membrane of the enterocytes. This results in internalization and 
eventual degradation of ferroportin (Nemeth et al., 2004b).  This limits the amount of iron that 
enters the circulation. Studies have shown that hepcidin also causes proteasomal degradation of 
DMT-1, found on the apical surface of the enterocyte (Brasse-Lagnel et al., 2011). Hepcidin 
levels are elevated in situations of iron overload and inflammation (Schmidt et al., 2008; 
Wrighting and Andrews, 2006). Under these circumstances, absorption of dietary iron is 
inhibited.  
Cellular mechanisms that regulate iron absorption 
When the demand for iron increases in the body, specific changes in the intestinal mucosal cells 
help to take up maximum iron from the diet. Some of the adaptation mechanisms include 
changes in gene transcription and mRNA stability and re-modelling of epithelium. (Gulec et 
al.,2014b). The transcriptional control of iron transporters is mainly by hypoxia- inducible 
factors and also by post transcriptional mechanisms that operate through the IRE-IRP system.  
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IRE-IRP system and intestinal iron transporters 
Under conditions of iron depletion, the IRE IRP system plays a major role in post-transcriptional 
stability of mRNA of DMT-1 and ferroportin. DMT-1 is strongly upregulated in conditions of 
iron deprivation (Collins et al., 2005). Two DMT-1 3′-splice variants exist, with and without the 
IRE. The variant with the IRE (+IRE) is the form predominantly expressed in the duodenum 
(Tchernitchko et al., 2002). When intracellular iron levels are low, IRPs bind to the 3’IRE 
leading to stabilization of the mRNA for DMT-1, which ultimately leads to increased protein 
production (Galy et al., 2008). 
Protein levels of ferroportin in intestinal cells are modified by its interaction with circulating 
hepcidin, which cause internalization and degradation of ferroportin, thereby blocking efflux of 
iron from enterocytes (Nemeth et al., 2004b). The presence of IRE in the 5’ UTR of the mRNA 
for ferroportin would predict that FPN translation would be inhibited when enterocytes are iron-
deprived. This seems inconsistent with the observed increase in duodenal FPN levels in states of 
iron deﬁciency (McKie et al., 2000). This contradiction is explained by the presence of two 
variants – one with an IRE and the other that lacks an IRE. Both are expressed in the duodenum. 
Evidence in mice suggests that the +IRE variant predominates in duodenum, even under 
conditions of iron restriction (Zhang et al., 2009). The observation of increased FPN expression 
in iron-deﬁcient enterocytes can partially be explained by the expression of FPN mRNA variants 
that lack IREs.  It could also reflect a dominant contribution of hepcidin-dependent regulation of 
FPN turnover, over translational control by IRPs (Galy et al., 2013). 
 
 
27 
 
Hypoxia and intestinal iron transporters: 
The epithelial cells of the intestine are in hypoxic condition. Enterocytes on the upper part of the 
villus furthest from the capillary bed in the lamina propria are most significantly affected 
(Colgan and Taylor, 2010).  
Cell-autonomous regulation of duodenal iron absorption in response to hypoxia is well 
documented. Studies have shown that acute hypoxia affects uptake of iron at the apical surface of 
enterocytes, independent of systemic factors such as the erythropoietic drive or hepcidin levels. 
Increased apical uptake of iron was observed in rats as early as 6 to 8 hours after onset of 
hypoxia (Hathorn, 1971). This early induction precedes changes in circulating levels of iron or in 
erythropoiesis (Raja et al., 1988) or a decrease in hepcidin levels (which occurs only after at least 
24 hours of hypoxia in mice and in humans) (Talbot et al., 2012). 
Hypoxia-inducible factors 
The body’s response to hypoxia is mediated by hypoxia-inducible factors (HIF), which are 
transcription factors (Semenza, 2001). Cells respond to conditions of insufficient oxygen 
availability by increasing the amount and activity of HIF transcription factors, which induce 
expression of a large number of genes involved in the response to hypoxia. HIF is a heterodimer 
made of an α-subunit and a β-subunit. α-subunit is a regulatory subunit. The β-subunit is 
constitutively expressed. There are 3 types of regulatory subunits - 1α, 2α and 3α (Tian et al., 
1997; Gu et al., 1998). The beta-subunit is also known as an aryl hydrocarbon nuclear 
translocator (ARNT). Oxygen-regulated HIF-1α and HIF-2α subunits form heterodimers with the 
constitutively expressed HIF-1β subunit, and bind hypoxia-responsive elements (HRE) in 
regulatory regions of DNA.               
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The specific roles of HIF-1α and HIF-2α have not been fully elucidated so far. In vitro, they both 
bind the same HRE.  They also share an overlapping set of target genes, but also activate the 
transcription of distinct genes (Recalcati et al., 2015) For example, both bind the HRE of 
erythropoietin (Epo), but only HIF-2α is important for Epo production in vivo. Glycolytic 
enzymes are regulated only by HIF-1α (Sowter et al., 2003). Proteins involved in absorption of 
iron from the intestinal lumen across the enterocyte into the circulation, viz DMT-1, Dcytb and 
Fpn, are direct targets of HIF-2α. 
Source: Recalcati et al., 2015 New perspectives on the molecular basis of the interaction between 
oxygen homeostasis and iron metabolism. Hypoxia 2015:3 93–103 
 
 
HIF-3α is structurally and functionally distinct. It is found in humans and other mammals. 
However, but its role and mode of action are not clear (Recalcati et al., 2015).  
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Figure 2.5. Regulation of intestinal iron transport related proteins by HIF-2α 
 
 
Source: Mastrogiannaki et al (2013).The gut in iron homeostasis: role of HIF-2 under normal and 
pathological conditions. Blood, volume 122, number 6 
 
Fate of HIF in normoxic conditions 
In a normoxic states, conserved proline residues of HIF-α undergo hydroxylation. This reaction 
is catalyzed by prolyl-4-hydroxylase domain enzymes (PHDs) (Epstein et al., 2001). These 
enzymes are dioxygenases; they utilize oxygen as substrate, 2-oxoglutarate as a cosubstrate, 
andiron and ascorbate as cofactors.  The 4-hydroxyprolines formed are then recognized by von-
Hippel Lindau (VHL) E3 ubiquitin ligase, which targets the HIF-α for proteasomal degradation 
(Maxwell et al., 1999). As the activity of PHDs is dependent on the availability of ferrous iron, 
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HIF-dependent transcription is also induced by iron deprivation, even under normoxic conditions  
(Salminen et al., 2015) 
A 2-oxoglutarate dependent dioxygenase, which hydroxylates a conserved asparagine residue of 
HIF-1α and HIF-2α, is factor inhibiting HIF (FIH) (Bishop and Ratcliffe, 2014). Hydroxylation 
of asparagine impairs interaction of HIF-α with transcriptional coactivators (p300 and CREB-
binding protein), thus inhibiting transcriptional activity HIF proteins (Dayan et al., 2006). 
Role of HIF in hypoxia and iron deficiency 
In hypoxia or iron deficiency, the enzyme activities of PHD, FIH are inhibited. Under such 
circumstances, HIF-α escapes degradation and translocate to the nucleus, where it dimerizes with 
the HIF-β subunit. This heterodimer then binds to the promoter or enhancer regions of target 
genes, at the hypoxia response elements (HREs), and recruits transcriptional coactivators, such 
as p300/CREB-binding protein, to activate transcription of the target genes (Wenger et al., 
2005). 
Hypoxia and iron homeostasis 
Effects of hypoxia on IRP-binding  
Studies suggest that hypoxia decreases IRP1 binding to IREs, and results in IRP1 acquiring 
aconitase activity. On the other hand, lack of oxygen increases IRP2 activity by stabilizing it 
(Cairo and Recalcati, 2007; Recalcati et al., 2010). F-box and leucine-rich repeat protein 
(FBXL5) is the key protein involved in stabilization of IRP2. It has a hemerythrin domain 
through which it senses iron and oxygen availability (Ruiz and Bruick, 2014). When iron and 
oxygen are fully available, FBXL5 accumulates in the cell, leading to proteasomal degradation 
31 
 
of IRP2. Oxygen deprivation promotes FBXL5 polyubiquitination and proteasomal degradation, 
via its hemerthyrin domain, leading to stabilization of IRP2 (Ruiz and Bruick, 2014).  
Regulation of HIF-2α mRNA by IRP1 
Presence of a 5′ IRE in the mRNA for HIF-2α showed the existence of another physiologically 
relevant connection between oxygen and iron sensing (Simpson and McKie, 2015). In normoxia, 
active IRP1 decreases basal HIF-2α translation. In hypoxia, the IRE/IRP1 interaction is impaired, 
leading to efficient translation of HIF-2α. In hypoxia, both increased translation and increased 
stability, due to inhibition of degradation by PHD, leads to increase in protein levels 
(Mastrogiannaki et al., 2013) 
In presence of an intracellular iron deficiency, IRP1 activity is increased, which leads to 
repression of HIF-2α translation. However, increased HIF-2α protein levels have been reported 
in the duodenum of iron-deﬁcient mice (Shah et al., 2009). This is because of stabilization of 
HIF-2α at the protein level, due to the decreased activities of PHDs in iron deficiency as shown 
in figure 2.6 (Mastrogiannaki et al., 2013). 
Hypoxic suppression of hepcidin 
The two hormones most important to regulate iron and oxygen homeostasis at the systemic level 
are hepcidin and erythropoietin, respectively. When erythropoietic activity is high, as in response 
to hypoxia or anemia, there is an increased absorption of iron to meet the higher demand of 
erythropoietic cells. This is accompanied by a strong inhibition of hepcidin expression (Kautz et 
al., 2014a). Studies suggest that hepatic HIF-2α inhibits hepcidin expression via an EPO-
mediated increase in erythropoiesis (Mastrogiannaki et al., 2012). Erythropoietin stimulates the 
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synthesis of erythroferrone, which is produced by erythroblasts and causes hepcidin suppression 
during stress erythropoiesis (Kautz et al., 2014b).  
Figure 2.6. Regulation of HIF-2α mRNA in duodenal enterocytes in iron-overloaded 
and iron-deficient states 
 
Source: Mastrogiannaki et al (2013). The gut in iron homeostasis: role of HIF-2 under normal 
and pathological conditions. Blood 122, 885–892. 
 
Effect of alcohol on iron metabolism 
Alcohol consumption has been shown to be associated with effects on iron homeostasis; these 
range from anemia to iron overload (Conrad and Barton, 1980; Kohgo et al., 2005). Alcohol by 
itself does not induce iron deficiency or anemia. Their presence in ALD is a result of 
gastrointestinal blood loss arising due to  the complications of ALD (Kimber et al., 1965). 
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Inadequate diet with nutrient deﬁcits, in alcoholic patients, can result in anemia with 
megaloblastic features. Anemia of chronic disease can also occur in patients with chronic ALD 
(Gonzalez-Casas et al., 2009). 
Mild alcohol consumption upto 2 drinks per day has been shown to be protective by reducing the 
risk of iron deficiency anemia, as wine has a high iron content and it increases iron absorption 
(Cook et al., 1995). On the other hand, heavy alcohol consumption (> 2 drinks /day) increases 
the risk of iron overload (Ioannou et al., 2004). Chronic alcohol consumption in moderate to 
excessive amounts is associated with elevation of serum ferritin concentrations and transferrin 
saturation. This can result in increased hepatic iron stores (Irving et al., 1988). In mild cases, iron 
accumulates in hepatocytes but in advanced cases of ALD, iron accumulation is seen in 
parenchymal cells and in Kupffer cells (Kohgo et al., 2005). Increased intestinal absorption of 
iron from the has been reported in chronic alcoholics (Duane et al., 1992). 
Alcohol has been shown to down-regulate hepcidin expression in cell lines and animal models. It 
did not alter the expression of transferrin receptor-1, ferritin, or cause activation of  IRP1 and 
IRP2 (Harrison-Findik et al., 2006). These results indicate that alcohol does not regulate hepcidin 
expression by altering the iron status of the cell, but possibly by a direct action on hepcidin. 
CCAAT/enhancer binding protein alpha (C/EBPα) is a transcription factor that regulates 
hepcidin expression. Alcohol was found to down-regulate the promoter activity and DNA-
binding activity of C/EBP alpha (Harrison-Findik et al., 2006). It also inhibited iron-mediated 
up-regulation of C/EBP activity in the liver (Harrison-Findik et al., 2007a). Down-regulation of 
hepcidin levels has also been demonstrated in patients with ALD (Dostalikova-Cimburova et al., 
2014). 
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Metabolism of alcohol induces oxidative stress in hepatocytes and Kupffer cells of the liver. This 
leads to the release of the pro-inflammatory cytokine, tumour necrosis factor (TNF-α), from 
activated Kupffer cells (Osna et al., 2017). TNF-α has been reported to down-regulate hepcidin 
expression in vitro. Thus, alcohol-mediated effects on hepcidin may involve hepatocytes and 
Kupffer cells of the liver (Nemeth et al., 2004a).  
Despite an iron overload (which is known to induce hepcidin) in the mice model used by 
Harrison-Findik et al.(2007), alcohol was found to down-regulate the expression of hepcidin in 
the liver, suggesting that alcohol may render hepatic synthesis of  hepcidin insensitive to 
increased body iron levels. (Harrison-Findik et al., 2007b) 
Alcohol-mediated down-regulation of hepcidin expression in the liver has also been reported 
result in to elevated expression of the proteins, DMT-1 and ferroportin, which are involved in the 
absorption of iron in the duodenum. The increase in expression of these proteins has been 
suggested to result in increased intestinal absorption of iron, and hence increased body iron 
levels (Harrison-Findik et al., 2007a). 
Effect of alcohol on HIF-2α expression  
There is evidence from mouse studies that chronic alcohol exposure reduces HIF -2α expression 
in the intestine (Wang et al., 2011). However, there are no studies till date regarding expression 
of duodenal HIF-2α in patients with alcoholic liver disease. 
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THE STUDY 
BACKGROUND TO THE STUDY 
Alcoholic liver disease (ALD) is often associated with dysregulation of iron homeostasis. 
Previous work from the investigators’ group has shown that expression of proteins involved in 
duodenal iron absorption were down-regulated in patients with ALD. Several factors are known 
to regulate expression of these duodenal proteins (which include divalent metal transporter 1 
[DMT-1], duodenal cytochrome b [Dcytb] and ferroportin). Hepcidin is one such factor. Serum 
hepcidin levels were deceased in these subjects and this did not explain the decreased expression 
of the duodenal proteins. Hypoxia-inducible factor-2α (HIF-2α) in the duodenum is another such 
regulator, which is known to induce the transcription of these duodenal proteins. Studies done in 
mice have shown that chronic alcohol ingestion decreased intestinal HIF-2α levels. However, it 
is not known whether HIF 2α expression is altered in patients with ALD.  
 
HYPOTHESIS 
Expression of duodenal hypoxia-inducible factor-2α (HIF-2α) may be altered in patients with 
alcoholic liver disease. 
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AIM 
The aim of this study was to test the hypothesis that expression of duodenal hypoxia-inducible 
factor-2α (HIF-2α) may be altered in patients with alcoholic liver disease. 
 
OBJECTIVES 
1. To determine protein expression of HIF-2α in duodenal mucosal samples, obtained from 
patients with alcoholic liver disease and from control subjects 
2. To determine gene expression levels of iron-related proteins (DMT-1, Dcytb and 
ferroportin) in the duodenal mucosal samples obtained from these patients  
3. To correlate HIF-2α protein expression with gene expression of duodenal iron-related 
proteins in these subjects  
4. To measure levels of serum iron, ferritin, high-sensitivity C-reactive protein (hs-CRP), 
total iron binding capacity (TIBC) and transferrin saturation in blood samples from 
patients with ALD and control subjects, and to correlate these with expression of the 
duodenal proteins listed above. 
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MATERIALS 
Equipment used  
1. Elix and Milli-Q water purification systems (Millipore, USA)    
2. Table-top refrigerated centrifuge (MPW R 350, MPW Poland)    
3. Minus 70
o
C freezer (Thermo Scientific, Massachusetts, USA) 
4. Glass homogenizer with teflon pestle (1 mL capacity) (Kimble-Kontes, USA)   
5. Agarose gel electrophoresis system (Medox Biotech, India)  
6. Gel documentation system (Alpha Innotech, USA)    
7. Applied Biosystem 2720 Thermocycler (Thermo Fisher Scientific, USA) for cDNA 
construction  
8. Real-time thermo cycler (Chromo4, Bio-Rad, USA) for qPCR  
9. Vertical gel electrophoresis for western blots (Bio-Rad, USA) 
10. Nanodrop spectrophotometer (Thermo Scientific, USA) 
Chemicals and reagents 
1.  Diethyl pyrocarbonate (DEPC), ethidium bromide, ethylene diamine tetraacetic acid (EDTA), 
formamide, formaldehyde, bromophenol blue, sodium hydroxide and TRI-reagent for RNA 
isolation were obtained from Sigma, India. 
2. Absolute alcohol was obtained from Hayman Ltd, England.   
3. Agarose was obtained from Genei, Bangalore, India.   
4. 3–morpholinopropane sulfonic acid (MOPS) was purchased from Sigma, India.   
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5. Reverse transcription core kit, SYBR Green PCR master mix kit was obtained from TaKaRa 
Bio, USA. 
6. Gene specific primers: beta-actin from Sigma, India; DMT-1, ferroportin and Dcytb from 
Eurogentec, Belgium.   
7. Tris-HCl, sodium acetate, sodium chloride, sodium deoxycholate, sodium dodecyl sulphate, 
sodium orthovanadate, sodium fluoride, glycerol, glycine, methanol, glacial acetic acid, Tween-
20, tetramethylethylenediamine, acrylamide, bisacrylamide, sodium chloride, potassium 
chloride, potassium dihydrogen phosphate and disodium hydrogen phosphate were obtained 
from Sisco Research Laboratories Pvt Ltd, Mumbai, India.  
8. Ammonium persulphate, 2-mercaptoethanol, Ponceau S were purchased from Sigma, India.  
9. Primary antibody for beta-actin (A5316) was obtained from Sigma Aldrich, India and for HIF 
2-alpha (NB100-122) from Novus Biologicals, USA.  
10. Secondary antibody for beta-actin (anti-mouse antibody) and HIF-2 alpha (anti-rabbit 
antibody) were obtained from Thermo Scientific, USA. 
11. Super signal West Dura extended duration substrate obtained from Thermo Scientific, USA 
for detection of chemiluminescence of bands obtained on western blots.  
All chemicals used were of analytical grade. 
Miscellaneous consumables used  
1.  Vacutainer tubes for blood collection (BD Biosciences, Plymouth, UK).    
2.  Micro-tubes and centrifuge tubes (1.5mL, 0.5 mL), and micro tips (Tarsons Products Private 
Limited, Kolkata, India).     
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METHODS 
The  study  was  approved  by  the  Institutional  Review  Board  (IRB)  at Christian Medical 
College (CMC), Vellore, India (IRB Min. No.9816 dated 07.01.16) (letter of approval in 
Appendix I). 
Subjects 
Patients in the Department of Hepatology and Gastroenterology at CMC, Vellore, who had been 
diagnosed to have alcoholic liver disease (ALD) and who required a medically-indicated upper 
gastrointestinal endoscopy were the subjects of the study. The following inclusion and exclusion 
criteria were employed to recruit patients: 
Inclusion criteria  
Patients who were diagnosed to have alcoholic liver disease based on a history of 20-30g (2 -3 
standard drinks) of alcohol intake per day for 5 or more years  
Diagnosis of cirrhosis, based on clinical and/or ultrasound evidence  
Such subjects who consented to participate in the study  
Exclusion criteria 
Patients who met the above criteria but showed evidence of other co-existent liver disease or 
evidence of viral hepatitis as a cause of liver disease 
An international normalized ratio (INR) above 1.5  
Not willing to take part in the study  
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Informed consent 
Once the study participants were identified based on the inclusion and exclusion criteria listed 
above, the study was explained to them and they were invited to participate. They were provided 
with an information sheet about the study.  This was available in the following languages: Tamil, 
English, Hindi, Telgu or Bengali. Written informed consent was obtained from those who were 
willing to participate in the study. The information sheet and informed consent form used are 
included in Appendix II. 
Recruitment 
Patients with ALD, who gave informed consent, were recruited as cases. Patients who underwent 
a medically-indicated upper GI endoscopy for evaluation of dyspepsia, who had no abnormalities 
in liver function and who were found to have no abnormal findings on endoscopy were recruited 
as controls; informed consent was obtained from them as well. 
Patients’ data 
A proforma was prepared to collect relevant clinical data on the patients recruited. This is shown 
in Appendix III. The investigator elicited relevant history from each patient and obtained clinical 
data (including relevant blood results) for each patient from their hospital records.    
Sample size   
A sample size calculation was done. In order to detect a change of 3.05 units in DMT-1 
expression in the duodenum, with 80% power and at 5% level of significance, the required 
sample size was found to 48 subjects in each of the 2 groups. Calculations done were based on 
preliminary data obtained by the research group in the Department of Biochemistry, who had 
been studying duodenal iron-related proteins in patients with ALD. 
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Formula  
n = ((Z α +Z 1-β) ^2 * 2 * S^2)/d^2  
where,  
Z α is 5% level of significance  
Z 1-β is the 80% power  
S = standard deviation   
d = 3.05 (mean change)  
Number of patients studied 
The total cost of antibodies and other reagents for western blot analyses and qPCR assays and for 
the blood tests was Rs.2780 per sample. The institutional research grant, which is available for 
postgraduates to carry out the work for their dissertation, was Rs 100000 for 2 years. This made 
it possible to do the various analyses only for a total of 36 patients. Hence 18 patients with ALD 
and 18 control subjects were studied. All the subjects in the study were recruited between June 
2016 and March 2017 
Sample collection 
After obtaining written informed consent, fasting blood samples were collected from the patients, 
before the endoscopic procedure. About 6 mL of blood was collected in BD vacutainer tubes 
(red), by venipuncture of the cubital vein. Two samples of duodenal mucosal tissue from the D2 
segment of the duodenum were collected in microtubes.  One of these contained 0.5 mL TRI- 
reagent and was used for gene expression studies. The other microtube was snap-frozen in liquid 
nitrogen and used later for western blot analyses. Both tubes with mucosal samples were stored 
at -70
o
C till further processing and analyses. 
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Processing of blood samples 
The blood samples collected were allowed to clot and centrifuged at 2500 rpm for 10 minutes to 
obtain serum; this was done within 2 hours of collection of blood.  
Storage of blood samples 
The serum obtained was divided into aliquots and stored at -70
ο
C, till analyses were carried out.  
When required, samples were thawed to room temperature and used for estimation of serum iron, 
TIBC, ferritin and hs-CRP.  
Estimation of serum iron 
Estimation of serum iron was carried out in the Department of Clinical Biochemistry, CMC, and 
Vellore.   
Analyzer used: Roche Cobas c 702 modular analyzer  
Principle of the method: Guanidine/ ferrozine spectrophotometric method  
Transferrin-bound ferric ions in the sample were released by guanidine, and reduced to ferrous 
form by means of hydroxylamine. Ferrous ions reacted with ferrozine to form a purple-colored 
complex. The absorbance of the sample was measured at 560 nm, using spectrophotometry. The 
intensity of the color obtained was directly proportional to the concentration of iron in the 
sample.  
Reference interval  
Male      -   60- 160 µg/dL  
Female   -   40-145 µg/dL   
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Estimation of total iron binding capacity (TIBC)  
Estimation of unsaturated iron-binding capacity (UIBC) was carried out in the Department of 
Clinical Biochemistry, CMC, Vellore.   
Analyzer used: Roche Cobas 8000 c 702 modular analyzer  
Principle of the method   
A known amount of ferrous iron was added to the sample at an alkaline pH. The ferrous ions 
bound to transferrin at iron-binding sites available. Unbound ferrous ions were measured using 
the ferrozine method (described above under the estimation of serum iron). The difference 
between the amount of ferrous ions added and the unbound ions measured was taken to be the 
unsaturated iron-binding capacity (UIBC) of the sample.   
 UIBC = [Amount of ferrous ion added] - [Amount of unbound ferrous ion]   
TIBC was calculated as the sum of serum iron concentration and the UIBC 
 TIBC = Serum iron + UIBC  
Reference interval   
Male       -   300-400 µg/dL  
Female   -   250-350 µg/dL 
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Calculation of transferrin saturation (TSAT) 
Transferrin saturation (TSAT) was calculated as the ratio of serum iron level and the total iron-
binding capacity of each sample, multiplied by 100.   
TSAT = (Serum iron / TIBC) x 100 
Estimation of serum ferritin 
Estimation of serum ferritin was done in the Department of Clinical Biochemistry, CMC, and 
Vellore.  
Analyzer used:  Siemens, ADVIA Centaur Immunoassay system Xpi, UK  
Principle of the method: Two-site sandwich immunoassay using direct chemiluminescence 
technology 
A polyclonal antibody tagged with acridinium was added to the reaction chamber.   A 
monoclonal mouse anti-ferritin antibody covalently bound with paramagnetic particles was 
added to the reaction chamber after addition of the sample. The paramagnetic particles acted as a 
solid phase for the immunoassay. Ferritin present in the sample formed a sandwich complex with 
the antibodies. The unbound antibodies were removed by aspiration. Acid reagent and base 
reagent were then added to initiate the chemiluminescent reaction. The intensity of photons 
released was measured and was directly proportional to the ferritin concentration in the sample.  
Reference interval 
Men and women > 50 years: 20-320 ng/mL  
Women < 50 years:              10-290 ng/mL 
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Estimation of hs-CRP  
Estimation of hs-CRP was carried out in the Department of Clinical Biochemistry, CMC, 
Vellore.   
Analyzer used: IMMULITE 2000 systems analyzer 
Principle of the method: Solid-phase chemiluminescent immunometric assay 
The solid-phase bead was coated with an anti-ligand. The liquid phase contained an anti-CRP 
murine monoclonal antibody, attached to the ligand, and alkaline phosphatase conjugated to 
rabbit polyclonal anti-CRP antibody in buffer. Pre-diluted patient sample and the reagent were 
incubated together with the anti-ligand-coated bead, for 30 minutes. The CRP in the sample 
formed an antibody sandwich complex. The unbound antibodies were removed.  Then a 
chemiluminescent substrate was added to the reaction tube; the intensity of photons released was 
measured and was directly proportional to the hs-CRP concentration in the sample  
Reference interval: < 3mg/L  
 
Processing of tissue samples 
RNA isolation  
Duodenal mucosal tissue was collected in microtubes containing 0.5 mL of TRI-Reagent (Sigma 
Aldrich) and stored at -70
o
C, and used for RNA isolation. RNA was isolated using TRI- Reagent 
protocol (Sigma Aldrich), according to the manufacturer’s instruction.  
Step 1: Mucosal samples in TRI- Reagent were homogenized using a glass homogenizer.  
Step 2: After homogenization, the samples were kept in room temperature for 5 minutes. 
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Step 3: Chloroform (0.1 mL for 0.5 mL of TRI-Reagent) was added to each tube and mixed for 
15 seconds. 
Step 4: The mixture was kept at room temperature for 15 minutes.  
Step 5: It was then centrifuged at 12000g for 15 minutes, at 4
o
C. Centrifugation separated the 
mixture into 3 phases; the upper aqueous phase contained RNA.  
Step 6: The aqueous phase was transferred to a fresh microtube, and 0.25 mL of isopropanol was 
added to it and mixed.  
Step 7: The mixture was kept at -20
o
C for 15 minutes.  
Step 8: It was then centrifuged at 12000g for 10 minutes, at 4
o
C. RNA that was precipitated 
formed a pellet on the side and bottom of the tube. 
Step 9: The supernatant was removed and the RNA pellet was washed by adding 0.5 mL of ice 
cold 75% ethanol. 
Step 10: This was centrifuged at 7500g for 5 minutes at 4
o
C. 
Step 11: The supernatant was discarded; the RNA pellet obtained was air-dried for 5-10 minutes, 
by placing them on ice and keeping the caps of the tubes open. .  
Step 12: DEPC water (25μL) was added to each tube with the RNA pellet; the sample was kept 
at 60
o
C for 10 minutes to dissolve the pellet.  
RNA quantitation   
A nano-spectrophotometer was used to estimate the quantity of RNA in each sample.   
Principle: Nucleic acids absorb ultraviolet light strongly at a wavelength of 260nm. An optical 
density reading of 1.0 at 260 nm was taken to indicate an RNA concentration of 40μg/mL. 
47 
 
The RNA extracted should be free of DNA and protein. The ratio of absorbance at 260 and 280 
nm and at 260 and 230 nm was used to assess the purity of RNA. If the A260/280 ratio was less 
than 1.8, or if there was evidence of phenol or guanidium isothiocyante contamination, the RNA 
was repurified by precipitation using ethanol.  
Ethanol precipitation 
Step 1: An aliquot (20 μL) of the RNA obtained was diluted to 100μL by adding DEPC water. 
Step 2: Sodium acetate (3M) 10μL (0.1 part by volume) was added and mixed using a vortex 
mixer. 
Step 3: Ice-cold ethanol (100%) (220 μL -2.2 parts by volume) was added and mixed thoroughly.  
Step 4: The tubes were placed at -20
o
C overnight.  
Step 5: The next day, the tubes were centrifuged at 12000g for 10 minutes. 
Step 6: Ice-cold ethanol (70%) (500 μL) was added to each tube and mixed; the mixture was 
centrifuged for 5 minutes at 12000g. 
Step 7: Ethanol was removed by decanting off the supernatant on top. 
Step 8: The tubes were kept open and placed inverted on tissue; they were then placed on ice and 
allowed to air-dry. 
Step 9: Each RNA sample was then dissolved in 25 μL of DEPC water. The concentration of 
RNA in each sample was quantitated, using a nano-spectrophotometer.  
If the A 260/ 280 ratio was more than 1.8 after ethanol precipitation, the RNA was considered to 
be of good quality. The integrity of the RNA isolated was confirmed by gel electrophoresis.   
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Confirmation of RNA integrity by gel electrophoresis 
The integrity of isolated RNA was confirmed by agarose gel electrophoresis. 
Step 1: 10X MOPS (morpholino-propanesulfonic acid) was prepared.   
In order to prepare 100 mL, 4.186 g of MOPS was dissolved in DEPC water. The pH of the 
solution was adjusted to 7.0, using 0.1 M NaOH. 
Sodium acetate (0.6804 gm) was then added to it (to give a final concentration of 50mM) and 
2mL of 0.5M EDTA (to obtain a final concentration of 10nM).  
Step 2: Preparation of agarose gel for electrophoresis (1.2% gel) 
To 34 mL of DEPC-treated water in a conical flask, 0.48 g of agarose was added. This was 
heated till the mixture boiled and the agarose melted.      
Step 3: To the melted agarose, 2.15mL of formaldehyde and 4 mL of 10 X MOPS and 7µL 
ethidium bromide was added. The contents were mixed well. This mixture was poured into a gel 
casting tray, combs were inserted into the mixture and it was allowed to set for 1 hour. 
Step 4: For sample preparation, 10µl of each RNA sample was mixed with 2.5µL of 10X MOPS, 
3.5µl of formaldehyde and 10µL of formamide.   
Step 5: The sample mixture was heated at 60
o
C in a dry bath for 15 minutes. 
Step 6: After this, the sample mixture was mixed with 4µl of bromophenol blue. 
Step 7: The running buffer, consisting of 30 mL of 10X MOPS and 270 mL DEPC-treated water, 
was poured into the tank. 
Step 8: The cast gel was placed in the buffer in the electrophoresis tank; samples were loaded 
into the wells in the gel. 
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Step 9: The samples were electrophoresed for 45 min, at 150 volts.    
Step 10: The RNA bands separated were visualized using an ultraviolet transilluminator in a 
ProteinSimple gel documentation system. Two distinct bands were seen, which represented the 
28S and 18S ribosomal subunits of RNA. When the 2 bands in each sample were found in an 
approximate band density ratio of 2:1, this was considered as evidence of RNA of good quality. 
cDNA construction by reverse transcription 
Reverse transcription of RNA was carried out using Prime script 1
st
 strand cDNA synthesis kit 
(TaKaRa). 
Principle   
In the presence of dNTP, random nanomers and reaction buffer, the reverse transcriptase enzyme 
converts RNA into cDNA 
Components of the kit 
For 200 reactions 
1.  5X PrimeScript Buffer 400 μl (contains dNTP Mixture and Mg2+) 
2.  PrimeScript RT Enzyme Mix I 100 μl (contains RNAse inhibitor) 
3.  Oligo-dT Primer (50 μM) 100 μl 
4.  Random 6 mers (100 μM) 400 μl 
5.  RNase-free dH2O 1 ml 
Step 1: The following reaction mixture was prepared and placed on ice.   
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For 1 reaction, 
Reagent Amount  
5х Prime script buffer 2μL 
RT enzyme mix 0.5 μL 
Oligo dT primer 0.5 μL 
Random 6mers 0.5 μL 
 
A master-mix was prepared by adding together all the above reagents in the proportions 
mentioned, for the required number of samples. 
Step 2: A volume of sample containing 500 ng RNA was added to a microtube.  
Step 3: DEPC water was added to each microtube so that the volume of RNA + DEPC water was 
6.5 μL. Master Mix (3.5 μL) was added to it to make the final volume of 10 μL. 
 RNA + DEPC water = 6.5 μL 
Master Mix              = 3.5 μL 
Step 4: Negative controls were also set up which were as follows:   
a. No template: This tube contained all the reagents except the RNA template. This was to 
confirm that the reagents and consumables used were not contaminated with DNA. 
b. No reverse transcriptase: This was a tube that contained all the above reagents except the 
reverse transcriptase. This negative control was used to confirm that there was no DNA 
contamination of the RNA sample used. 
Step 5: All the reaction tubes were mixed and centrifuged in a microfuge for a few minutes.  
Step 6: The tubes were incubated under the following conditions:  
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For reverse transcription- 37
o
C for 15 minutes  
Inactivation of reverse transcriptase-  85
o
C for 5 seconds  
Cooling of samples - 4
o
C for 10 minutes 
Step 7: The cDNA obtained was stored at -20
o
C till real-time PCR analysis.  
Real-time polymerase chain reactions (PCR) or quantitative PCR (qPCR) 
The cDNA obtained was amplified by real-time PCR for DMT-1, ferroportin and Dcytb genes. 
Beta-actin was used as the house-keeping gene. The PCR reactions were set up in 96-well plates. 
To ensure reproducibility, all samples were assayed in quadruplicates. 
The following gene-specific primers were used for the reactions.  
Gene Primer sequence  Reference  
Beta actin  Forward  
Reverse 
5’-AGAGCTACGAGCTGCCTGAC -3’ 
5’-AGCACTGTGTTGGCGTACAG -3’ 
(Sukumaran et al., 
2014b) 
DMT-1  Forward  
Reverse 
5’-TGCTGCTATCATTCCAACACTAAATT-3’  
5’-ATATAGCCTGGTTAAGAATCATGCA-3’         
(Sukumaran et al., 
2014b)   
Dcytb Forward  
Reverse 
5’-GTCACCGGCTTCGTCTTCA-3’  
5’-CAGGTCCACGGCAGTCTGTA-3’                            
(Sukumaran et al., 
2014b) 
Ferroportin  Forward  
Reverse 
5’- TGACCAGGGCGGGAGA -3’ 
5’- GAGGTCAGGTAGTCGGCCAA-3’ 
(Jacolot et al., 2008) 
 
The concentrations of primers and annealing temperatures for each gene of interest were 
standardized for all 4 genes.  
The details are given below. 
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Standardization of qPCR assays 
Gene Sequence 
accession 
number 
Length of 
the primers  
Amplicon 
length 
Primer 
concentration 
Annealing 
temperature 
Beta-actin  NM_001101.3 
 
Forward:20 
Reverse:20 
184 250 nM 60
o
C 
DMT-1 NM_000617.2  
 
Forward:26 
Reverse:25 
104 250 nM 60
o
C 
Ferroportin  NM_014585.5 
 
Forward:16 
Reverse:20 
67 250 nM 60
o
C 
Dcytb  NM_024843.3 
 
Forward:19 
Reverse:20 
62 250 nM 60
o
C 
 
Validation of qPCR assays 
Sl. 
No 
Gene 
Standard 
curve slope 
R
2
 of 
standard 
curve 
Linear 
dynamic 
range 
(cDNA 
dilution) 
Primer 
dimer 
(melting 
curve 
analysis) 
Ct of 
amplification (if 
any) in the no 
template 
control NTC 
1 Beta-actin -3.405 0.997 1:5 to 1:625 
In no template 
control(NTC) 
37 
2 DMT-1 -3.244 0.999 1:5 to 1:3125 
In no template 
control (NTC) 
33 
3 Ferroportin -3.065 0.997 1 to 1:625 No  None  
4 Dcytb -3.331 1 1:5 to 1:3125 No  None  
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Dilution of cDNA templates 
cDNA (5 μL) was diluted with 45 μL of DEPC water (1:10 dilution) and used for qPCR 
reactions. The concentration MgCl2 in the reaction mixture was optimized to 5mmol/L for all the 
genes studied.  
The following were the components and quantities for a single PCR reaction: 
Component  Volume  
Diluted cDNA template  2μL 
SYBR green master mix  5 μL 
Gene-specific primer mix  0.25 μL 
DEPC water   2.75 μL 
 
A master mixture was prepared with the above reagents (excluding the cDNA).  This was done 
using the specified proportions, for 106 reactions (96 reactions + 10% extra for pippeting loss). 
Eight μL of the master mixture was added into each of 96 wells; 2 μL cDNA was added to each 
well in the plate as follows.  
Model of a 96-well plate set-up for qPCR assays 
 1 2 3 4 5 6 7 8 9 10 11 12 
A A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 No T 
B A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 No T 
C C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 No RT 
D C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 No RT 
E A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 No T 
F A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 No T 
G C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 No RT 
H C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 No RT 
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After adding the cDNA and master mix, the wells in the plate were closed tightly using 
transparent caps.  The contents of each well were mixed, and the plate was briefly centrifuged for 
2 minutes at 2000 RPM. The plate was then placed in the thermal cycler, which was programmed 
as shown below. 
Thermal cycler program 
Step  Temperature  Time 
1 Hot start  95
o
C 3 minutes  
2 Denaturation  95
o
C 10 seconds 
3 Annealing and extension 60
o
C 60 seconds 
4 Reading taken 
5 Steps 3, 4 and 5 were repeated for 39 more cycles. 
6 Melting curve analysis was done for the temperature range of 50-95
o
C. 
Readings were taken every 10 seconds, for every 1
o
C increase in 
temperature 
7 Samples were cooled and maintained at 4
o
C for 10 minutes.  
 
After completion of PCR assays for each gene of interest, the log fluorescence data graph and 
melting curves were obtained.   
Calculation of gene expression 
The cycle threshold (Ct) value was the outcome parameter obtained at the end of the PCR assays. 
If any of the Ct values of the quadruplicates was found to be discordant, the value of that 
A1- A11: cDNA of samples from patients with ALD 
C1-C11: cDNA of samples from control patients  
No T- No template; No RT- No reverse transcriptase  
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particular tube was ignored and the average Ct of the remaining replicates was taken as final Ct 
of that particular gene.   
The relative expression of the target gene was calculated in comparison with an internal 
reference gene (beta-actin), using cycle threshold (Ct) values. Controlling for errors using 
internal reference gene is commonly done in qRT-PCR assays. It is presumed that the internal 
reference gene does not change under disease conditions and can hence control for errors, while 
performing qPCR. This minimizes variability between samples.  
Each target gene data was normalized relative to beta-actin. The Ct value of beta-actin for each 
sample was subtracted from that of the gene of interest (DMT-1, ferroportin and Dcytb). This 
value was referred to as the ∆Ct value.   
The average ∆Ct of all controls for each gene was calculated and this average value was 
subtracted from the ∆Ct of each sample for samples from both cases and controls. The resulting 
value was referred to as ∆∆Ct. Fold-change in gene expression was calculated by the formula  
                     Fold change = 2
-∆∆Ct  
 
The fold-change of 3 genes studied in all the samples was calculated.  
 
MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) -
guidelines which describe the minimum information necessary for qPCR evaluation. This 
information in the form of checklist is attached as Appendix IV. 
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WESTERN BLOT ANALYSES  
Tissue homogenization  
The tissue samples were homogenized in RIPA buffer.  
Lysis buffer 
1. RIPA (radio-immunoprecipitation assay buffer)  
Composition of RIPA:  
Sodium chloride 140mM 
Tris HCl 10mM 
EDTA 1.5mM 
Triton X 1% 
Sodium deoxycholate 0.1% 
SDS 0.1%  
2. Protease inhibitor cocktail (100μL for 10 mL buffer) 
3. Phenyl methyl sulfonyl fluoride (PMSF) (1mM) 
4. Sodium orthovanadate (200μM) 
5. Sodium fluoride (50mM) 
All the above constituents were mixed together. This solution was prepared fresh each time, for 
homogenization. 
Step 1:  0.5 mL of the RIPA buffer was added to the tissue sample in the microtube.  The tissue 
was homogenized using a teflon pestle.  
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Step 2: The samples were incubated on ice for 15 minutes. 
Step 3: They were centrifuged at 12000g for 10 minutes, at 4
o
C, for the cell debris to settle.  
Step 4: The supernatant was transferred to fresh micro tubes. Four aliquots were made.   
Step 5: All the aliquots were stored at -70
o
C till further analyses.  
Protein estimation in the RIPA lysates 
The concentration of protein in each lysate was estimated, using the Pierce BCA protein assay kit 
(Thermo Scientific). This was done to calculate the amount of each sample to be loaded in the 
gel for western blot analyses. 
The contents of the Pierce BCA protein kit were: 
1. BCA reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1 M NaOH)  
2. BCA reagent B (4% cupric sulphate)  
3. Albumin standard (2mg/mL in 0.9% saline and 0.05% sodium azide) 
Principle of the assay 
The cupric ions were reduced to cuprous ions by protein in an alkaline medium (the biuret 
reaction). A purple colour product was formed by the reaction of BCA molecules with cuprous 
ion. It exhibited a strong absorbance at 562 nm. The absorbance was almost linear with 
increasing protein concentrations (20-2000µg/mL) and it was measured in micro plate reader. 
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Preparation of diluted albumin standards 
Vial  Volume of diluent 
(μL) 
Volume and source of 
BSA (μL) 
Final BSA 
concentration (μg/mL) 
A 125 375 of stock 1500 
B 325 325 of stock 1000 
C 175 175 of vial A 750 
D 325 325 of vial B 500 
E 325 325 of vial D 250 
F 400 0 0 ( Blank) 
 
Assay 
Reagent A and reagent B were mixed in the proportion of 50:1 to prepare the working reagent. 
The assay was done in 96-well microplates. For each well, 200 µl of the working reagent was 
used. The assay was done in duplicates for each sample.  
Step 1: Samples and standards (20 μL of each) were added to wells in the plate as shown below.  
Model of microplate set-up for protein estimation 
 1 2 3 4 5 6 7 8 9 10 11 12 
A A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
B A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
C A13 A14 A15 A16 A17 A18 A19 C1 C2 C3 C4 C5 
D A13 A14 A15 A16 A17 A18 A19 C1 C2 C3 C4 C5 
E C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 C17 
F C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 C17 
G C18 C19 S0 S1 S2 S3 S4 S5 B    
H C18 C19 S0 S1 S2 S3 S4 S5 B    
 
A1-A19: Samples from patients with ALD; C1-C19: Samples from control patients  
S0-S6: Albumin standards; B: Blank  
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Step 2: 200 μL of working reagent was added to each well.  
Step 3: The contents of the wells were mixed thoroughly for 30 seconds, using a plate shaker.   
Step 4: The plate was closed with a cover and incubated at 37
o
C for 30 minutes.   
Step 5: After incubation, the plate was cooled to room temperature. A microplate reader was 
used to take readings at 562 nm.  
Step 6: The average absorbance of the wells containing blanks was subtracted from each of 
readings for the standards and samples. 
Step 7: A standard curve was prepared by plotting the blank-corrected reading of each standard 
against its concentration (µg/mL).  
Step 8: The standard curve was used to determine the protein concentration in each sample.  
y = 0.001060x + 0.104000 
R² = 0.995745 
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After determining the protein concentration in each sample, the volume of sample required to 
load 30μg protein in each well of the gel was calculated.  
Reagents for western blotting analyses 
1. Loading buffer (2х Laemmli buffer) 
4% Sodium dodecyl sulphate SDS  
10% 2-mercaptoethanol  
20% glycerol  
0.004% bromophenol blue  
0.125 M Tris HCl  
The pH of this solution was adjusted to 6.8, using 0.1 N NaOH if necessary. 
2. Running buffer (10X) 
For preparing 1000 mL, 
25 mM Tris base (30.25 g) 
190mM glycine (144.13 g) 
0.1% SDS (10 g) 
The above chemicals were added together to make a final volume of 1000 mL, using distilled 
water.  The pH of this solution was adjusted to 8.3, using 0.1 N HCl. 
3. Transfer buffer  
For preparing 1000 mL,  
25 mM Tris Base (30.25 g) 
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190mM glycine (144.13 g) 
0.1 % SDS (1 g)  
The above chemicals were added together to make a final volume of 1000 mL, using distilled 
water. Methanol (200 mL for 1000 mL) (final concentration of 20%) was added to the mixture 
just before use.  
4. Phosphate-buffered saline 
For 1000 mL, 
Sodium chloride (8 g) 
Potassium chloride (0.2 g) 
Disodium hydrogen phosphate (1.44 g) 
Potassium dihydrogen phosphate (0.24 g) 
The above chemicals were added together and dissolved in distilled water to make a final volume 
of 1000 mL. 
5. Wash buffer 
PBS with Tween 20 (0.1%) 
For every 100 mL of PBS, 0.1 mL of Tween 20 was added. 
6. Blocking buffer 
Non-fat dry milk powder was dissolved in wash buffer (5g for 100 mL PBS-T) (5% w/v)  
7. Running gel: Solution A and solution C  
Solution A: For 100 mL  
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Sodium dodecyl sulphate (0.4 g) 
Tris (18.165 g) 
Tetramethylethylenediamine (0.2 mL)  
The above chemicals were added together and dissolved in distilled water to make a final volume 
of 100 mL The pH of the solution was adjusted to 8.8, using 0.1 N HCl. 
Solution C: For 50 mL 
Acrylamide (20 g) 
Bisacrylamide (0.532 g) 
The above chemicals were added together and dissolved in distilled water to make a final volume 
of 50 mL. The solution was filtered using Whatman filter paper. 
8. Stacking gel- Solution B and solution D  
Solution B: For 100 mL 
Sodium dodecyl sulphate (0.4 g) 
Tris (6.72 g) 
Tetramethylethylenediamine (0.278 mL) 
The above chemicals were added together and dissolved in distilled water to make a final volume 
of 100 mL. The pH was adjusted to 6.8 by adding 0.1N HCl. 
Solution D: For 100 mL 
Acrylamide (20 g) 
Bisacrylamide (0.532 g) 
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The above chemicals were added together and dissolved in distilled water to make a final volume 
of 100 mL. The solution was filtered using Whatman filter paper. 
Sample preparation 
1. The RIPA lysate of each sample was taken from the -70
o
C freezer and allowed to thaw on ice. 
2. A volume of sample (containing 30 μg of protein) was transferred to a microtube, labeled 
appropriately.  
3. 6.5 μL of loading buffer was added to the sample.  
4. Then running buffer was added to make a final volume of 32.5 μL.  
3. The samples were boiled at 95
0
 C for 5 minutes.   
Protein separation by vertical gel electrophoresis 
Apparatus 
This consists of a thin and a thick plate, a spacer, the holder for the glass plate and a trough. The 
thin plate is placed in front of the thick plate. The 2 plates are separated by a spacer of 1 mm 
thickness. They are held in position on the holder. The trough is placed at the bottom of the 
plates.  
Running gel (10%) 
Ammonium persulphate (APS) (0.05 g) was dissolved in 500μL of distilled water, using a vortex 
mixer.  
The following reagents were added in a test tube 
Solution A (1.2 mL), Solution C (1.2 mL), Distilled water (2.35 mL) and APS (0.05 mL) 
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After mixing solutions A, C and distilled water, APS was added and the mixture was poured into 
the space between the glass plates in the holder. The gel was allowed to polymerize for 45 
minutes. 
Stacking gel (7%) 
The following reagents were added in a test tube.  
Solution B (0.5 mL), Solution D (0.5 mL), Distilled water (950 μL) and APS (0.05 μL) 
After mixing together the above reagents, the mixture was poured into the space between the 2 
plates. A plastic comb was inserted into the top of the space between the plates, to create wells. 
The gel was allowed to polymerize for 45 minutes. After the gel polymerized, the assembly of 
the 2 plates was removed from the holder and the comb was gently removed. The assembled 
plates were placed in a holder that was then placed in an electrophoresis chamber.  The chamber 
was filled with running buffer. 
Loading of samples 
1. Thirty micrograms of protein was loaded into each well in the gel. 
2. Molecular weight markers were loaded in wells at both ends of the gel. 
3. A positive control for HIF-2α was loaded in one of the wells. 
4. Proteins in the gel were electrophoresed at 50 volts for the first 20-30 minutes (till the samples 
had reached the running gel). 
5. After this, the voltage was increased to 80 V; electrophoresis was allowed to continue till the 
tracker dye reached near the bottom of the gel.  
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Blotting 
At the end the electrophoretic separation, the proteins on the gel were transferred on to a 
membrane (polyvinylidene difluoride [PVDF]). 
1. Two membranes of 8.5 х 5.5 cm were activated by placing them in methanol for 15 seconds 
and then MilliQ water for 2 minutes. It was then placed in the transfer buffer.  
2. The glass slides containing the gel were placed in flat dish containing transfer buffer; the 
slides were separated.  
3. The stacking gel was carefully removed; the gel was left in transfer buffer for 10 minutes. 
4. The following were assembled for protein transfer: Sponge, 2 filter papers, gel, PVDF 
membrane, 2 filter papers and sponge. 
This assembly was immersed in transfer buffer. It was then placed in the cassette used for 
transfer. Care was taken to ensure that there was no air bubbles trapped in the assembled 
sandwich, by gently rolling a small test tube over it.  
5. The cassette was placed in the transfer tank with the membrane on the cathode side and the gel 
on the anode side. The transfer tank was kept in a box containing ice.  
6. The transfer was allowed to take place at 80 V for 2 hours.  
Blocking 
At the end of the transfer, the membrane was removed from the cassette. It was rinsed in water 
and stained with Ponceau solution to ensure that the proteins had transferred adequately. The 
stain was then rinsed off with three washes, using PBS-T, for about 10 minutes each time. The 
membrane was then immersed in blocking buffer (PBS-T) and subjected to gentle rocking for 2 
hours. At the end of this, the membrane was removed; it was placed on a glass plate to be cut, 
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using the molecular weight markers for reference, so that different portions of the membrane 
could be used for incubation with different primary antibodies.  The molecular weight of HIF2-
alpha is 118 kDa and that of beta-actin is 42 kDa. Hence, the membrane was cut between 70 and 
100 kDa. 
Incubation with primary antibody 
The membranes were incubated with primary antibodies against the proteins of interest. This was 
done overnight at 4
o
C, using a roller. The concentration of primary antibody used for beta-actin 
was 1:1000; that for HIF2-alpha was 1:500. These dilutions were made using blocking buffer. 
Incubation with secondary antibody 
After incubation with the primary antibody, the membrane was washed three times in PBS-T, for 
10 minutes each time. The membrane was incubated with HRP-conjugated secondary antibody; 
this was done for 2 hours, at room temperature. The concentration of the secondary antibody 
used was 1:2500 (2μL of secondary antibody was added to 5 ml blocking solution). For beta-
actin, an anti-mouse antibody was used. For HIF 2 alpha, an anti-rabbit antibody was used. After 
this incubation, the membranes were washed thrice in PBS-T, for 10 minutes each time.  
Imaging 
To detect the protein bands, SuperSignal West Dura Extended Duration Substrate kit from 
Thermo Scientific, USA, was used. The kit had SuperSignal West Dura Luminol/Enhancer 
solution and SuperSignal West Dura Stable peroxide solution. A chemiluminescent substrate for 
detecting horseradish peroxidase (HRP) on immunoblots was used. HRP conjugated to the 
secondary antibody catalyzed the conversion of peroxide to release nascent oxygen. The 
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colourless substrate was turned to a chemiluminescent compound by the nascent oxygen 
released. This was visualized on an imaging system. 
Equal parts of peroxide solution and enhancer solution were mixed to prepare the working 
reagent. The membrane was submerged in the mixture for 1 minute. Excess substrate was 
drained off. Then the membrane was placed in a gel documentation system (Alpha Innotech). 
The proteins bands were visualized by the chemiluminescent signals they emitted. These signals 
were captured using a CCD camera-based imager. The intensity of the bands for beta-actin and 
HIF2-alpha were obtained using Image J software. The intensity of the HIF-2-alpha protein band 
was expressed relative to that of the band for beta-actin, which was used as a loading control.  
 
STATISTICAL ANALYSIS 
The Statistical Package for the Social Sciences (SPSS), version 16, was used to analyze the data 
obtained. Shapiro Wilk’s test was used to determine if the data was normally distributed. If 
normally distributed, then mean and standard deviation were calculated. The means of the 
quantitative variables was compared, using independent t-test. If the variable was not normally 
distributed, median and interquartile range was calculated. Mann-Whitney U test was used for 
comparison of data that were not normally distributed.  A p value of less than 0.05 was taken to 
indicate statistical significance in all cases. Bivariate correlation analyses were done using 
Pearson correlation for variables with normal distribution and Spearman’s rank correlation for 
variables that are not normally distributed.  
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RESULTS 
Thirty six males were recruited for the study, as per the inclusion and exclusion criteria described 
in the study protocol. Of these, 18 subjects were diagnosed to have ALD and 18 subjects were 
age-matched controls. 
Data for some parameters were not available from the medical records for all the subjects 
recruited. Only available data were analyzed. The number of subjects for whom each set of data 
was available is indicated in the tables showing the results of this study.   
Shapiro-Wilk test was used to determine normality of the data. Data for age, total protein, MCV, 
serum iron and TIBC were found to be normally distributed. Those for hemoglobin, total 
bilirubin, direct bilirubin, serum albumin, AST, ALT, ALP, transferrin saturation, serum ferritin, 
WBC counts and hs-CRP were found to have skewed distributions.  
Normally distributed data are shown as means + SD, while data with a skewed distribution are 
shown as medians with inter-quartile ranges. 
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a. Characteristics of the subjects 
Table 6.1 shows relevant characteristics of the 2 groups.  
Table 6.1. Baseline characteristics 
Characteristics 
 
Control subjects Patients with ALD 
Number of subjects  
 
18 18 
Males / Females  
 
18 / 0 18 / 0 
Mean age in years (±SD) 
 
48.3 ± 7.3 47.8 ± 7.2 
Mean duration of alcohol use 
in years (±SD) 
 
 
0 15 ± 6.3 
 
All the subjects recruited were males. The mean ages of subjects in the 2 groups were similar. 
Only those with ALD had a history of long-term alcohol consumption. 
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b. Hematological parameters 
Table 6.2 shows the hemoglobin levels and mean corpuscular volume of the subjects.  
Table 6.2. Hematological parameters  
Parameter 
 
Control subjects  Patients with ALD p value  
Hemoglobin (g/dL)  
 
 
MCV (fL) 
 
14.5 (13.5-15.1) 
(n=18) 
 
81.4 ± 7.4 
(n=14) 
11.5 (10.2-12.9) 
(n=18) 
 
90.5 ± 9.7 
(n=18) 
 
< 0.001 
 
 
0.006 
 
 
Hemoglobin levels were significantly lower and MCV significantly higher in the group with 
ALD. However, the mean values for MCV were within the reference range (80-100 fL) for both 
groups.  
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c. Parameters of liver function 
Table 6.3 shows the parameters of liver function.  
Table 6.3. Parameters of liver function 
Parameter Control subjects  
(n=18) 
 
Patients with ALD 
(n=18) 
p value 
Total protein (g/dL) 
 
Serum albumin (g/dL) 
 
Albumin: Globulin  
 
Total bilirubin (mg/dL) 
 
Direct bilirubin (mg/dL) 
 
AST(IU/L) 
 
ALT (IU/L) 
 
ALP (IU/L) 
 
7.4 ± 0.2 
 
4.6 (4.3-4.7) 
 
1.5 (1.3-1.7) 
 
0.5 (0.38-0.82) 
 
0.2 (0.14-0.22) 
 
24 (19-29.2) 
 
26 (19.7-36) 
 
72.5 (67.25- 85.25) 
 
7.5 ± 0.6 
 
3.2 (2.6-4) 
 
0.73 (0.49-1.2) 
 
3.4 (1.4-5.5) 
 
1.9 (0.6-3.1) 
 
74 (36.5-112) 
 
33.5 (23.5-57.5) 
 
110.5 (85.5-134) 
0.732 
 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
0.097 
 
<0.001 
  
Serum levels of total bilirubin, direct bilirubin, AST and ALP were significantly higher in 
subjects with ALD than in control subjects. Serum levels of albumin and the albumin-globulin 
(AG) ratio were significantly lower in subjects with ALD.  Serum total protein levels were 
similar in both groups.  
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d. Parameters of inflammation 
Table 6.4. Parameters of inflammation 
Parameter  
 
Control subjects 
 
Patients with ALD p value 
 
WBC count 
(cells/cu.mm) 
 
hs-CRP (mg/L) 
 
 
7900 (5850-9200) 
(n=13) 
 
0.94 (0.42-2.37) 
(n=18) 
 
7600 (4850-9050) 
(n=18) 
 
5.8 (3.4-9.9) 
(n=18) 
0.798 
 
 
<0.001 
 
Total WBC counts and serum levels of hs-CRP were used as markers of inflammation. Of these, 
hs-CRP was significantly higher in subjects with ALD. Total WBC counts were similar in both 
groups.  
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Figure 6.1. Serum iron levels in control subjects and those with ALD  
 
 
 
Serum iron levels were similar in both groups.  
. 
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Figure 6.2. TIBC in the control subjects and those with ALD  
 
 
 
 
TIBC was significantly lower in subjects with ALD than in control subjects. 
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Figure 6.3. Transferrin saturation in control subjects and those with ALD  
 
 
Data are shown as box and whisker plots, showing medians and interquartile ranges. The median 
is shown by the line within the box; the bottom and top edges of the boxes are the 25
th
 and 75
th
 
percentiles, respectively. Transferrin saturation was significantly higher in subjects with ALD 
than in control subjects. . 
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Figure 6.4. Serum ferritin levels in control subjects and those with ALD  
 
Data are shown as box and whisker plots, showing medians and interquartile ranges. The median 
is shown by the line within the box; the bottom and top edges of the boxes are the 25
th
 and 75
th
 
percentiles, respectively. Values outside the top and bottom 5th percentiles are shown as outliers. 
Serum ferritin was significantly higher in those with ALD than in control subjects.   
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Confirmation of integrity of RNA isolated 
RNA isolated from the duodenal mucosal samples was subjected to agarose gel electrophoresis. 
The presence of two distinct bands in the gels, corresponding to the 28S and 18S ribosomal 
subunits of RNA, was taken to confirm the integrity of RNA obtained from each sample. Figure 
6.5 shows the representative image of a gel in which RNA samples were electrophoresed.  
 
            Figure 6.5. Image of agarose gel showing 18S and 28S subunits of RNA isolated 
The amount of RNA obtained from one of the samples from patients with ALD was found to be 
too low to use for analysis. Hence, this sample was excluded from qPCR analysis. 
 
28 S rRNA  
18 S rRNA  
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Figure 6.6. Gene expression of DMT-1 in control subjects and those with ALD  
 
Data are shown as box and whisker plots showing medians and interquartile ranges. The median 
is shown by the line within the box; the bottom and top edges of the boxes are the 25
th
 and 75
th
 
percentiles, respectively. Values outside the top and bottom 5th percentiles are shown as outliers. 
Gene expression of DMT-1 (mRNA levels) was similar in the two groups. 
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Figure 6.7. Gene expression of ferroportin in control subjects and those with ALD  
 
Data are shown as box and whisker plots, showing medians and interquartile ranges. The median 
is shown by the line within the box; the bottom and top edges of the boxes are the 25
th
 and 75
th
 
percentiles, respectively. Values outside the top and bottom 5th percentiles are shown as outliers.  
Gene expression of ferroportin was similar in the two groups.  
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Figure 6.8. Gene expression of Dcytb in control subjects and those with ALD  
 
Data are shown as box and whisker plots, showing medians and interquartile ranges. The median 
is shown by the line within the box; the bottom and top edges of the boxes are the 25
th
 and 75
th
 
percentiles, respectively. Values outside the top and bottom 5th percentiles are shown as outliers.  
Gene expression of Dcytb was similar in the two groups.  
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Protein expression of HIF-2α 
Representative blots of HIF-2α in duodenal mucosal samples of controls (n=13) and patients 
with ALD (n=15) are shown in figure 6.9.   The amount of protein obtained from 5 control 
duodenal mucosal samples and 3 samples from patients with ALD were too low to be quantified. 
Hence, these samples were not used for western blot analyses. Whole-cell protein extract of 
HepG2 cells, treated with 100μM CoCl2 for 8 hrs, was used as the positive control for HIF-2α 
(+ve control) (Piret et al., 2002). 
 
Figure 6.9. Representative western blots for HIF-2α 
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118 kDa 
β actin 
42 kDa 
 
42 
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Figure 6.10. Protein expression of duodenal HIF-2α in control subjects and those with ALD  
 
Data are shown as box and whisker plots, showing medians and interquartile ranges. The median 
is shown by the line within the box; the bottom and top edges of the boxes are the 25
th
 and 75
th 
percentiles, respectively. Values outside the top and bottom 5th percentiles are shown as outliers. 
Protein levels of HIF-2α were similar in the two groups.  
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Correlation analysis was done using Spearman rank analysis. 
* p < 0.05, ** p < 0.01 
Hemoglobin levels were positively correlated with TIBC. Serum iron and ferritin levels 
correlated positively and significantly with transferrin saturation. Serum ferritin and transferrin 
saturation correlated negatively with TIBC. 
Table 6.5. Correlation analyses of iron-related parameters (n=36) 
   
Hb (g/dL) 
Serum iron 
(ug/dL) TIBC (ug/dL) 
Transferrin 
saturation 
(%) 
Serum ferritin 
(ng/mL) 
 Hb (g/dL) Correlation 
Coefficient    -  0.085  0.389
*
  -0.089  -0.174 
p value  
   -  0.621  0.019  0.607   0.309 
Serum iron 
(ug/dL) 
Correlation 
Coefficient  0.085   -  -0.222  0.891
**
  0.090 
p value  0.621   -  0.194  < 0.001  0.600 
TIBC (ug/dL) Correlation 
Coefficient  0.389
*
  -0.222   -  -0.602
**
  -0.738
**
 
p value  0.019  0.194   -  <0.001  <0.001 
Transferrin 
saturation (%) 
Correlation 
Coefficient  -0.089  0.891
**
  -0.602
**
   -  0.351
*
 
p value  0.607  <0.001  <0.001   -  0.036 
Serum ferritin 
(ng/mL) 
Correlation 
Coefficient  -0.174  0.090  -0.738
**
  0.351
*
   - 
p value 
 0.309  0.600  < 0.001  0.036   - 
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Table 6.6. Correlation analyses of iron-related parameters and inflammatory parameters  
    WBC count 
(cells/cu.mm) 
(n=31) 
 
hs-CRP  
(mg/L) 
(n=36) 
 
 Hb (g/dL)  Correlation Coefficient  0.264 
 
 -0.461
**
 
 p value  0.152 
 
 0.005 
Serum iron (ug/dL)  Correlation Coefficient  0.093 
 
 -0.093 
 p value  0.620 
 
 0.588 
TIBC (ug/dL)  Correlation Coefficient  0.004 
 
 -0.567
**
 
 p value  0.982 
 
 <0.001 
Transferrin saturation 
(%) 
 Correlation Coefficient  0.074 
 
 0.150 
 p value  0.694 
 
 0.383 
Serum ferritin (ng/mL)  Correlation Coefficient  0.160 
 
 0.495
**
 
 p value  0.390 
 
 0.002 
   
Correlation analysis was done using Spearman rank analysis. 
**p < 0.01 
Levels of hs-CRP correlated negatively with hemoglobin and TIBC, and positively with serum 
ferritin.  
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Table 6.7. Correlation analyses of expression levels of DMT1, Dcytb, Fpn and HIF-2α with 
iron-related parameters 
    DMT-1  
mRNA 
expression 
(n=35) 
Ferroportin 
mRNA 
expression 
(n=35) 
Dcytb 
 mRNA 
expression 
(n=35) 
HIF-2α 
protein 
expression  
(n=28) 
 Hb (g/dL)  Correlation 
Coefficient 
 -0.221  -0.232  0.135  0.245 
 p value 
 0.202  0.180  0.441  0.208 
Serum iron 
(ug/dL) 
 Correlation 
Coefficient 
 -0.019  -0.030  0.053  0.105 
 p value 
 0.914  0.864  0.761  0.594 
TIBC 
(ug/dL) 
 Correlation 
Coefficient 
 0.323  0.268  0.134  -0.128 
 p value 
 0.059  0.119  0.443  0.517 
Transferrin 
saturation 
(%) 
 Correlation 
Coefficient 
 -0.096  -0.081  0.015  0.119 
 p value 
 0.585  0.643  0.930  0.548 
Serum 
ferritin 
(ng/mL) 
 Correlation 
Coefficient 
 -0.312  -0.373
*
  -0.120  0.306 
 p value 
 0.068  0.027  0.492  0.113 
 
Correlation analysis was done using Spearman rank analysis. 
* p < 0.05 
Ferroportin mRNA levels correlated negatively with serum ferritin levels.  
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Table 6.8. Correlation analyses of expression levels of DMT1, Dcytb, Fpn and HIF-2α with 
inflammatory parameters 
 
 
Correlation analysis was done using Spearman rank analysis. 
No significant correlations were seen between the expression levels of DMT1, Dcytb, Fpn and 
HIF-2α and inflammatory parameters. 
Correlational analysis of the data from the control group showed similar observations, as shown 
for the whole group of 36 subjects. 
 
 
 
    DMT-1 
mRNA 
expression 
 
Ferroportin 
mRNA 
expression 
 
Dcytb  
mRNA 
expression 
 
HIF-2α 
protein 
expression 
 
 WBC count 
(cells/cu.mm) 
 Correlation 
Coefficient 
-0.278 -0.203 0.209 -0.165 
 
 
p value 0.137 0.281 0.268 0.431 
 
 
n 30 30 30 25 
hs-CRP (mg/L)  Correlation 
Coefficient 
-0.159 -0.077 -0.207 -0.096 
 
 
p value 0.363 0.660 .0232 0.628 
  
n 
35 35 35 28 
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Table 6.9. Significant correlations in patients with ALD 
 
   DMT-1 
mRNA 
expression  
Fpn  
mRNA 
expression  
TIBC 
(ug/dL)  
Tf sat 
(%)  
Serum 
ferritin 
(ng/mL)  
WBC 
count 
(cells/mm
3
)  
hs-CRP 
(mg/L)  
 DMT-1 
mRNA 
expression  
Correlation 
Coefficient  
- 0.725
**
 0.538
*
 -0.471 -0.520
*
 -0.574
*
 -0.289 
 p value  
 
. 0.001 0.026 0.057 0.033 0.016 0.260 
Ferroportin 
mRNA 
expression  
Correlation 
Coefficient  
0.725
**
 - 0.527
*
 -0.598
*
 -0.686
**
 -0.602
*
 -0.196 
p value 
 
0.001 . 0.030 0.011 0.002 0.011 0.451 
TIBC (ug/dL)  Correlation 
Coefficient  
0.538
*
 0.527
*
 - -0.519
*
 -0.655
**
 -0.267 -0.687
**
 
p value 0.026 0.030 
 
. 0.027 0.003 0.285 0.002 
Transferrin 
saturation 
(%)  
Correlation 
Coefficient  
-0.471 -0.598
*
 -0.519
*
 - 0.342 0.201 0.071 
p value 0.057 0.011 0.027 . 0.165 0.423 0.779 
 
Serum 
ferritin 
(ng/mL)  
Correlation 
Coefficient  
-0.520
*
 -0.686
**
 -0.655
**
 0.342 - 0.360 0.496
*
 
p value 0.033 0.002 0.003 0.165 . 0.142 0.036 
 
WBC count 
(cells//mm
3
)  
Correlation 
Coefficient  
-0.574
*
 -0.602
*
 -0.267 0.201 0.360 - 0.274 
p value 0.016 0.011 0.285 0.423 0.142 . 0.272 
 
hs-CRP 
(mg/L)  
Correlation 
Coefficient  
-0.289 -0.196 -0.687
**
 0.071 0.496
*
 0.274 - 
p value 0.260 0.451 0.002 0.779 0.036 0.272 . 
 
Correlation analysis was done using Spearman rank analysis. 
* p < 0.05, ** p < 0.01 
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In patients with ALD, 
 DMT-1 mRNA levels correlated positively with FPN mRNA levels 
 FPN mRNA levels correlated negatively with transferrin saturation 
 Both DMT-1 and FPN mRNA levels were found to have  
               a. Positive correlation with TIBC  
               b. Negative correlations with serum ferritin and WBC counts  
 Serum ferritin levels were found to have positive correlation with hs-CRP and negative 
correlation with TIBC 
 hs-CRP levels were found to have negative correlation with TIBC 
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SUMMARY OF RESULTS 
1. Levels of hemoglobin and serum albumin, and TIBC were significantly lower in subjects with 
ALD than in control subjects. 
2. Serum levels of ferritin, hs-CRP, AST and ALP, and MCV and transferrin saturation were 
significantly higher in subjects with ALD than in control subjects. 
3. Serum levels of iron, total protein and ALT were similar in both groups. 
4. Gene expression of proteins involved in duodenal iron absorption (DMT-1, Dcytb and 
ferroportin) and protein expression of HIF-2α were similar in the two groups. 
5. Correlation analysis of data from the whole group showed that serum ferritin levels were 
positively correlated with transferrin saturation and hs-CRP and negatively with TIBC and 
ferroportin mRNA levels. Hemoglobin levels were positively correlated with TIBC. Serum iron 
levels correlated positively with transferrin saturation and hs-CRP levels correlated negatively 
with hemoglobin levels and TIBC.  
6. Correlation analysis of data from patients with ALD showed that FPN and DMT-1 correlated 
positively with each other; mRNA levels of both of these proteins correlated negatively with 
serum ferritin and WBC counts, and positively with TIBC. FPN mRNA also showed negative 
correlations with transferrin saturation. Serum ferritin levels were found to have positive 
correlation with hs-CRP and negative correlation with TIBC. 
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DISCUSSION 
Alcohol consumption results in a wide spectrum of pathological effects in the liver including 
steatosis, hepatitis and cirrhosis. However, only a small proportion of patients progress from 
steatosis to hepatitis to cirrhosis, despite continued and heavy alcohol consumption. This 
suggests that, apart from alcohol, other factors play a role in progression of the disease. One such 
factor, which has been postulated to promote disease progression in ALD, is iron (Magdaleno et 
al., 2017). 
It has been reported that hepatic iron overload is associated with ALD (Basaranoglu et al., 2013; 
Milic et al., 2016). However, this reported association is often based on elevated levels of 
surrogate markers of iron status, such as serum ferritin levels and transferrin saturation (Bell et 
al., 1994; Kohgo et al., 2005). In the few studies where hepatic iron stores were directly assessed 
(by histopathology and/or estimation of hepatic tissue iron in liver biopsy samples), the 
prevalence of increased iron stores in patients with ALD was found to be highly variable. For 
example, it varied from 57% in the study by Jakobovits et al (Jakobovits et al., 1979) to 29% in 
that by Chapman et al (Chapman et al., 1982). No stainable iron was detectable in hepatic 
biopsies in the study by Lundvall et al; in fact, estimation of liver iron in this study showed 
significantly decreased hepatic iron stores among patients with alcoholic cirrhosis (Lundvall et 
al., 1969). Hence, iron overload does not appear to be an invariable feature of ALD. 
Anemia is common among patients with ALD (Gonzalez-Casas et al., 2009). The cause for 
anemia in such patients is multifactorial; it may be due to iron deficiency (IDA) as a result of 
gastrointestinal blood loss, poor nutrition, impaired duodenal iron absorption, or a combination 
of these (Kimber et al., 1965; Gonzalez-Casas et al., 2009). On the other hand, alcohol has been 
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shown to directly suppress erythropoiesis (Hourihane and Weir, 1970). In addition, ALD is 
known to be a chronic inflammatory condition and the anemia seen in this condition may be due 
to anemia that is associated with inflammation (AI) (Lewis et al., 2007). 
In the present study, the prevalence of anemia among patients with ALD was found to be 77%. 
These patients had mild-to-moderate anemia (as per WHO criteria for the diagnosis of anemia).  
The mean serum iron levels in patients with ALD were similar to those in control patients. 
However, patients with ALD had lower TIBC and higher MCV, transferrin saturation and serum 
ferritin levels, when compared to control patients. This suggests that the cause for anemia was 
probably not iron deficiency; rather, these findings, along with that of increased serum hs-CRP 
levels, which is a marker of systemic inflammation, suggests that the anemia may be secondary 
to inflammation.   
There is no physiological mechanism to excrete iron from the body.  Intestinal absorption of iron 
is regulated to maintain iron homeostasis in the body. There are very few studies that have 
determined expression of duodenal proteins involved in the absorption of non-heme iron in 
patients with ALD.  Dostalikova-Cimburova et al (2014) have reported decreased serum 
hepcidin levels, increased mRNA expression of DMT-1 and FPN and increased protein levels of 
FPN in patients with ALD, when compared to control subjects. However, earlier work done in 
the Department of Biochemistry at CMC, Vellore, on patients with ALD showed different 
results. In these studies, expression of duodenal DMT-1 and ferroportin was lower in patients 
with ALD than in control subjects, despite co-existence of low levels of hepcidin (unpublished 
data). These observations prompted the study of factors other than hepcidin that regulate 
duodenal iron absorption, leading to the present study.  
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It is known that local factors in the duodenal mucosa regulate proteins involved in the absorption 
of iron. HIF-2α is a transcription factor, which is  known to play an important role in the 
transcriptional regulation of duodenal iron transporters (Mastrogiannaki et al., 2009). The 
intestinal mucosa is exposed to a relatively hypoxic environment; this stabilizes HIF-2α 
(Mastrogiannaki et al., 2009). Intestine-specific knock-out of HIF-2α in mice resulted in 
decreased expression of DMT-1, FPN and DCYTB (Mastrogiannaki et al., 2012). On the other 
hand, feeding mice a diet that was deficient in iron increased HIF-2α protein levels, leading to 
increased expression of these proteins (Shah et al., 2009).  
It has been shown, in mice, that chronic alcohol exposure reduced HIF-2α protein levels in the 
intestine (Wang et al., 2011). Therefore, we hypothesized that alcohol-induced alterations in 
HIF-2α expression may underlie the decreased expression of duodenal proteins involved in iron 
absorption, observed in patients with ALD. To the best of our knowledge, there are no published 
studies till date that have looked at the expression of duodenal HIF-2α in patients with ALD. 
The results of the present study showed no difference in HIF-2α protein levels (determined by 
western blotting) between patients with ALD and control subjects. In the 18 patients with ALD 
in this study, gene expression of DMT, FPN or Dcytb were similar to those in the control group, 
unlike what had been observed earlier. The small sample size of the present study is likely to 
account for these differences, as the earlier study had a larger sample size. When data from both 
studies were combined, the overall findings were that expression levels of the duodenal proteins 
were decreased. Stored samples from the earlier study were also used to determine protein 
expression of HIF-2α. However, it was found that it was not possible to detect HIF-2α protein in 
these samples, necessitating the present study to obtain fresh samples of duodenal mucosa.  
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 As mentioned earlier, anemia increases expression of iron transporters, while inflammation 
decreases it (Gulec et al., 2014). In this study, patients with ALD were anemic and showed 
evidence of systemic inflammation. It is possible that the opposing effects of anemia and 
inflammation in the patients with ALD may also underlie the observation that expression levels 
in these patients were similar to those in control subjects. Achieving adequate sample size and 
estimating serum hepcidin, TNF-alpha and hepatic iron content in these patients will give a 
better idea of the various factors that are at play in this setting. 
There was no correlation seen between protein levels of HIF-2α and mRNA expression of  
DMT-1, FPN or Dcytb, tending to suggest that HIF-2α may not play a major role in the 
regulation of these duodenal iron transporters in patients with ALD. Nevertheless, it should be 
kept in mind that HIF-2α  is an extremely short-lived protein (Bracken et al., 2006). Changes in 
duodenal HIF-2α  in mice have been shown only when they were exposed to stimuli (such as low 
iron diet or hypoxia) that robustly up-regulated HIF-2α levels (Shah et al., 2009). There are no 
studies that we have been able to find that have shown a decrease in protein levels in HIF-2α, 
thus causing a down-regulation of duodenal proteins involved in iron absorption. Technical 
difficulties exist in detection of small changes in the levels of short-lived proteins such as HIF-
2α. Taking this into consideration, although there is no significant difference in protein levels of 
HIF-2α in the present study, its role in regulation of intestinal iron transporters in ALD cannot be 
ruled out. In addition, due to financial constraints associated with an MD thesis, it was possible 
to study only 18 patients with ALD and 18 control subjects, while the calculated sample size was 
48 in each group. It would be necessary to achieve the required sample size to draw definitive 
conclusions about the possible role (or not) of HIF-2α in regulating duodenal proteins involved 
in iron absorption in patients with ALD. 
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Systemic as well as local inflammation in the intestine is known to affect iron absorption 
(Wessling-Resnick, 2010). The effects of systemic inflammation are mainly mediated by its 
effects on hepcidin, which is elevated in such conditions (Nemeth et al., 2003).  Increased serum 
levels of hepcidin down-regulate duodenal iron transporters (Frazer et al., 2002), resulting in 
decreased iron absorption. Local inflammation, on the other hand, results in increased levels of 
pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα), which can act directly 
on the enterocytes to down-regulate duodenal iron transporters. This effect is independent of 
hepcidin (Laftah et al., 2006). ALD is known to be associated with intestinal inflammation, 
increased intestinal permeability and increased levels of TNFα (Kawaratani et al., 2013).  Serum 
CRP is widely used as a marker of systemic inflammation (Pearson et al., 2003). In this study, 
hs-CRP levels were found to be significantly higher in patients with ALD than the control group. 
In addition, WBC counts (another marker of inflammation) negatively correlated with DMT-1 
and FPN mRNA. It is therefore possible that inflammation may also play an important role in the 
regulation of duodenal iron transporters in patients with ALD in this study. 
Correlation analysis of the data in this study revealed several interesting results. WBC counts 
showed a significant negative correlation with mRNA expression of DMT-1 and FPN in patients 
with ALD, suggesting the effect of inflammation on these proteins. Serum ferritin showed a 
significant positive correlation with hs-CRP in patients with ALD. No correlations were found 
between ferritin and other markers of iron status, such as serum iron levels and transferrin 
saturation. This suggests that the cause of elevated ferritin in these patients was inflammation 
rather than iron overload. 
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These results of this study are different from the one by Dostalikova-Cimburova et al. The 
similarities and important differences between these studies are shown in the tables below, which 
may explain the differing observations. 
Similarities between the present study and that by Dostalikova-Cimburova et al (2014) 
 Dostalikova-Cimburova et al 
study 
Present study  
 
Cases ALD patients (n=24) ALD patients (n= 18) 
 
Control subjects Patients with dyspeptic 
symptoms(n=30) 
 
Patients with dyspeptic 
symptoms(n= 18) 
Hemoglobin levels  
 
Hb significantly lower in 
patients with ALD than in 
control subjects  
Hb significantly lower in 
patients with ALD than in 
control subjects  
Serum iron  Similar in both groups  Similar in both groups  
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Differences between the present study and that by Dostalikova-Cimburova et al (2014) 
 Dostalikova-Cimburova et al 
study 
Present study  
 
Sex: Males = 35  ; females = 19 
 
All males  
 
Mean age of  the 
subjects: 
 
57.4 years (similar in both 
groups) 
 
48 years (similar in both groups) 
 
Cases sub-divided 
into those 
 
with anemia                 n=8 
with iron overload       n=6 
without iron overload n=10 
 
Not done as the total numbers were 
small (n=18) 
Serum ferritin  Not significantly different 
between the two groups  
Ferritin was significantly higher in 
patients with ALD  
 
Transferrin saturation  
 
Not significantly different 
between the two groups 
 
Transferrin saturation was 
significantly higher in patients with 
ALD, but was within the reference 
range 
 
hs-CRP  Not done  Increased in patients with ALD 
when compared to controls  
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mRNA expression  Expression of DMT-1, FPN 
and TFR1 genes increased 
significantly in patients with 
ALD as a whole; and more 
pronounced in the subgroups 
with anemia and without iron 
overload. 
 
Expression of DMT-1,FPN1, 
DCYTB similar in cases and 
controls  
 
Protein expression of 
iron transporters  
Protein expression of DMT-1, 
FPN, Dcytb and HEPH done 
by western blotting 
 
FPN protein levels were higher 
in patients ALD. The other 
proteins were similar.  
 
Protein expression of DMT-1 and 
FPN1 was not done as a part of the 
dissertation.   
HIF-2α protein 
expression 
Not done This was carried out as part of this 
study; protein expression of HIF-2α 
was similar in the 2 groups.   
Seum hepcidin  Decreased in patients with 
ALD  
 
Not done as a part of the 
dissertation 
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As shown in the tables above, there are many differences between the present study and that by 
Dostalikova-Cimburova et al (2014). Hence, the result of the 2 studies cannot be directly 
compared.  
The present study included only male patients with ALD; female patients with ALD are rare in 
the Indian setting. It is known that there are gender and ethnicity-related differences in iron 
metabolism and liver diseases  (Harrison-Findik, 2010). The inflammatory status of patients with 
ALD was not determined in the study by Dostalikova-Cimburova et al (2014). In the present 
study, patients with ALD had higher hs-CRP levels, which may contribute to the low mRNA 
expression of proteins involved in iron absorption. 
To the best of our knowledge, this is the first study to explore the role of HIF-2α in regulation of 
duodenal proteins involved in iron absorption in patients with ALD.   
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CONCLUSION 
The results of this study show that HIF-2α does not appear to be altered in patients with ALD. 
However, study of an adequate sample size is required to confirm these findings. 
 
LIMITATIONS OF THE STUDY 
1. The calculated sample size for this study was 48 subjects in each group. Due to financial 
constraints and limited time available for carrying out work for an MD dissertation, it was 
possible to study only 18 patients in each group. This small sample size is a major limitation of 
the study. 
2. Estimation of the parameters listed below would help elucidate the various mechanisms 
involved in dysregulation of iron homeostasis in patient with ALD. However, these could not be 
done as part of this dissertation work, due to constraints of time and funds. On-going work in the 
lab is aimed at addressing these lacunae.  
 Serum hepcidin levels to better understand the complex regulation of intestinal proteins 
involved in iron absorption 
 Protein expression levels of DMT-1, FPN and Dcytb which would help in understanding 
the regulation at post-transcriptional levels 
 Estimation of TNFα in duodenal mucosal samples which would be a definitive marker of 
local intestinal inflammation. 
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APPENDIX II: PATIENT INFORMATION SHEET (ENGLISH)                                
Duodenal HIF-2α and iron-related proteins in alcoholic liver disease 
As a part of the investigation of your current medical problem, the doctor taking care of you has 
advised you to undergo an endoscopy, during which a tube will be passed into your stomach and 
small intestine, so that the doctor can see whether there is any problem in these organs. During 
the procedure, the doctor may take a small piece of tissue from the stomach or intestine, so that 
certain tests can be done with this tissue in order to find out more about your illness. 
The Department of Biochemistry, in association with Department of Hepatology and 
Gastroenterology, is carrying out a study on all patients who undergo such an endoscopy to 
understand changes in the way iron is handled in the body in the patients who have liver disease, 
produced by intake of alcohol. Iron levels in the liver are often higher than normal in this 
situation. It sometimes worsens the disease. We do not know fully why this happens. We would 
like to study this problem to understand it better. We also wish to study patients who do not have 
liver disease due to alcohol intake and whose doctors have advised them to have an endoscopy as 
part of the tests being done to diagnose the problem.  
In order to carry out these studies, we need to have a very small biopsy from the small intestine. 
This will be taken at the same time that the doctor looks at the inside of your stomach and 
intestine. We request your permission to take this piece of tissue. You will not feel any extra 
discomfort on account of this. We also request permission to take a sample of blood from you. 
This is to help us study what happens to iron in the blood.  
The biopsy and blood samples that we request will be used purely for scientific research. The 
collection of 10 ml of blood and biopsy sample will not cause any harm to your health in any 
foreseeable manner. Any sample or part of it that may remain at the end of the study will be 
stored and used for related research in the future. All your personal information obtained by us 
from you will be kept confidential. 
 
You may not benefit directly from the study. However, if you are willing to allow us to take 
these samples, it will help us try to understand why iron collects in liver in those who drink 
alcohol. This knowledge may help improve treatment for the disease. However, if you do not 
wish to be part of this study, you are free to refuse to give permission for this. The treatment you 
continue to receive in this hospital will be exactly the same whether you choose to be part of this 
study or not. 
If you have any doubts or questions regarding the study, please contact one of the following:     
Dr.S.Mathuravalli, Department of Biochemistry, CMC, Vellore.   Phone 9566901857    
Dr.A J Joseph, Professor and Head, Department of Gastroenterology, CMC, Vellore. Ph: 0416 
2282496 
Dr.Eapen CE, Professor, Department of Hepatology, CMC, Vellore.  Ph: 0416-2283629 
Dr.Molly Jacob, Professor and Head, Department of Biochemistry, CMC, Vellore. 
 Ph: 0416-2284267 
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PATIENT INFORMATION SHEET (TAMIL)                                 
ஆய்வில் பங்கேற்பவருக்ோன தேவல் தாள்  
மது சார்ந்த ேல்லீரல் க ாய் உள்க ாரின் குடல் ஹிப்  2 ஆல்பா மற்றும் இரும்பு  
 ிலைேள் 
உயிர் வேதியியல் துறை கல்லீரல் வ ோயியல் துறை  மற்றும் குடல்,இறரப்றை வ ோயியல் 
துறை இறைந்து மது சோர்ந்த கல்லீரல் வ ோய் உள்வ ோரின் குடல் ஹிப்  2 அல்ைோ மற்றும் 
இரும்ைின்  ிறைகற  கண்டைிய ஆய்வு வமற்ககோள்  உள்வ ோம் . 
மது சோர்ந்த கல்லீரல் வ ோய் உள்வ ோரின் இரத்தத்தில் இரும்ைின் அ வு அதிகமோக 
உள் து .அதிக இரும்பு அ வுகள் வ ோறய வமலும் வமோசமோக்கி ேிடும் .இதற்கோன 
கோரைத்றத கண்டைிய இந்த ஆரோய்ச்சி உதவும். 
தங்கள் வ ோய் கண்டைிதைின் ஒரு ைகுதியோக உள்வ ோக்கியின் மூைம் ேயிறு மற்றும் 
சிறுகுடல் ைகுதிகள் ைோர்றே இடப்ைடும். அப்வைோது சிைித வு சிறுகுடல் வமற்ைகுதி திசு 
எடுக்கப்ைட்டு ஆய்வு கசய்யப்ைடும்.இந்த திசு எடுத்து ஆய்வு கசய்ய தங்கள் அனுமதி 
வேண்டுகிவைோம் .இந்த திசு எடுப்ைதோல் தங்களுக்கு எந்தேித தீங்கும் ஏற்ைடோது . 
இந்த ஆய்வுக்கோக  1 ௦ மில்ைி அ வு இரத்தம் வதறே ைடுகிைது .தோங்கள் சுய 
ேிருப்ைத்துடன் இரத்தம் தர வேண்டுகிவைோம் .ஆய்வுக்கோன இந்த இரத்தம் தோங்கள் இதர 
ைரிவசோதறனக்கு ேரும் கைோழுது தங்கள் அனுமதியுடன் கைற்று ககோள் ப்ைடும்.மீதமோகும் 
இரத்தம் வசகரிக்கப்ைட்டு ைின் ஆரோய்சிக்கோக உைவயோகப்ைடுத்தப்ைடும். 
ஆரோய்ச்சிக்கோக அைியப்ைடும் தகேல்கள்  ம்ைகமோன முறையில் ைோதுகோக்கப்ைடும் .இந்த 
ஆய்ேில் ைங்கு கைறுேதோல் தோங்கள் வ ரடியோக ையன் கைை இயைோது .ஆனோல் இதன் 
மூைம் அைியப்ைடும் தகேல்கள் ைிற்கோைத்தில் இந்வ ோறய சரியோக றகயோ  உதவும் . 
இந்த ஆரோய்ச்சியில் ைங்குகைை ேிருப்ைமில்றை என்ைோல் தயங்கோமல் கூைைோம் .
அதனோல் இந்த மருத்துேமறனயில் தங்களுக்கு தரப்ைடும் வசறே ைோதிக்கப்ைடோது. 
இந்த ஆய்வு குைித்த சந்வதகங்கள் மற்றும் கதோடர்புக்கு கீழ்க்கண்ட  ைர்கற  அணுகவும்  
மரு. மதுரேள் ி, உயிர் வேதியியல் துறை, வைோன் 9566901857  
மரு. வ ோசப், குடல் மற்றும் இறரப்றை துறை, வைோன்   0416-2282496 
மரு. ஈகைன், கல்லீரல் வ ோயியல் துறை, வைோன் 0416-2283629 
மரு. வமோைி வ க்கப், உயிர் வேதியியல் துறை, வைோன் 0416- 2284297 
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PATIENT INFORMATION SHEET (HINDI)                                 
  रोगी सूचना पत्र - आंतों (डुओडनेम) के एक टुकडे और रक्त के एक नमून ेके लिए अनुरोध 
अध्य्यन शीर्षक: शराब के सेवन से जिगर सम्बधंधत बीमारी में ग्रहणी एच. आई. एफ. २ आल्फा और िोहे से 
सबंधंधत प्रोटीन की मात्रा। 
आपकी मौिूदा धचककत्सीय समस्या की िाचं के तहद,आपकी देखभाि कर रहे डॉक्टर ने आप को एंडोस्कोपी सिाह 
दी है  जिसके दौरान एक  ट्यबू आपके पेट और छोटी आंत में  से गज़ुरेगी ताकक आपके डॉक्टर देख सकें  कक इन भागों 
में कोई समस्या है कक नहीं। प्रकिया के दौरान, डॉक्टर इन भागों से एक छोटा सा टुकडा िेगें ताकक उनपर 
ननजचचत परीक्षण कर आपके रोग के बारे में और िानकारी प्राप्त हो सके।  
िैव रसायन ववभाग, हेप्टोिोिी और गसै्रोएंटरोिॉिी ववभाग के सहयोग से, एक अध्ययन कर रहें हैं एंडोस्कोपी से 
गिुरने वािे ऐसे सब मरीिों पर, ताकक शरीर में होने वािे िोहे के ननयतं्रत्रत में पररवततन को िांच सके ऐसे रोधगयों  में 
जिन्हें शराब के सेवन से जिगर सम्बधंधत बीमारी है। इस जस्िनत में अक्सर जिगर में िोहे का स्तर सामान्य 
से अधधक हो िाता है। इससे कभी कभी रोग त्रबगड िाता  है। ऐसा क्यों  होता है, हमें  परूी तरह से 
पता नही ंहै। हम यह बेहतर ढंग से समझने के लिए, इस समस्या का अध्ययन करना चाहत ेहैं। ऐसा 
करने के लिए हमें छोटी आतं से बहुत छोटी बायोप्सी करने की िरूरत है। इस े डॉक्टर उस समय िेंगें 
िब आपके पेट और आंत के अदंर ट्यबू डािी िाएगी। हम इस ेिेने के लिए आपकी अनमुनत का 
अनरुोध करत ेहैं। इस के कारण आपको कोई अधधक नकुसान नहीं होगा। हम आपस ेरक्त का नमनूा 
प्रदान करने की अनमुनत भी मााँगत ेहैं जिसस ेहम रक्त में िोहे से सबंधंधत अध्ययन में आसानी होगी।  
एकत्र रक्त और वसा ऊतकों के नमनूों अनसुधंान प्रयोिनों के लिए ही इस्तमेाि ककए िाएंगे। 10 
लमिीिीटर रक्त और बायोप्सी नमनेू के सगं्रह से आपके स्वास््य को  ककसी ननकटतम तरीके से कोई 
नकुसान नहीं होगा। आपके द्वारा  प्रदान की गई  धचककत्सा एव ंननिी सचूना गोपनीय रखी िाएगी।   
आपको इस अध्ययन से प्रत्यक्ष रूप से िाभ नहीं होगा। िेककन, अगर आप अध्ययन में भाग िेने और 
नमनेू उपिब्ध कराने के लिए तयैार हैं, तो यह हमें शराब का सेवन करने वािे रोधगयां के जिगर में िोहा 
क्यों िमा हो िाता है, यह समझने में मदद प्रदान करेगा। यह ज्ञान डॉक्टरों को इस रोग के इिाि को 
बेहतर बनाने में मदद कर सकता है। अगर आप रक्त और वसा ऊतकों के नमनूों को देने की इच्छा नहीं 
रखत े, तो आप ऐसा कहने के लिए स्वततं्र हैं। यह आपके अस्पताि में प्राप्त होत ेउपचार को प्रभाववत 
नहीं करेगा।  
अगर आपको अध्यययन के बारे में कोई सदेंह या प्रश्न हैं, तो ननम्न में से एक से सपंकष  करें: 
1. डॉ एस. मधुरवजल्ि, िैव रसायन ववभाग, सी एम सी , वेल्िोर, फोन 9566901857 
2. डॉ ए.िे. िोसेफ , प्रोफेसर और हेड, गसै्रोएटंरोिॉिी ववभाग , सी एम सी , वेल्िोर । फोन: 0416 2282496 
3. डॉ ऐपन सी. ई., प्रोफेसर, हेप्टोिोिी ववभाग, सी एम सी , वेल्िोर । फोन: 0416-2283629 
4. डॉ मौिी िेकोब, प्रोफेसर और हेड, िैव रसायन ववभाग , सी एम सी , वेल्िोर । फोन: 0416-2284267 
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PATIENT INFORMATION SHEET (TELUGU)                                 
 
                                    రక్త నమూనా మరియు చినన ప్రేగు యొక్క నమూనా సరక్రణ క ై సమాచార పతే్ము  
పరిశోధన అంశం :    త్ాే గుడు వలన క్లుగు లివర్ వ్యాధిలో HIF 2α మరియు ఐరన్ మరియు చినన ప్రగు సంబంధిత్  ఆమాా లు    
గురించి . 
మద్యపానంవలన కలుగు కాలేయ సంబంధిత వ్ాయధులలో శరరీరమునంద్ు ఇనుము యొకక ప్రకరియ జీవ రసాయన ప్రకరియలో 
మారపులు గురపంచి బయోకేమిస్్టర ,ీ గ్ాయస్ర ీ ఎంట్రర లలజి, మరియు హేపాట్రలజి విభాగములు సంయుకతంగ్ా ప్రిసశోధన 
నిరవహిసుత న్నారప. ఈ వయదియంద్ు సాధనరణ సాా యి కంట్ి అధికముగ్ా ఇనుము నిలవలు కాలేయములో చేరపట్, దనని వలన 
కొనిా సారపు  వ్ాయధి ఇంకా అధికమగుట్ జరపగును. కాని అది ఎంద్ు వలన అనా ప్ూరిత వివరములు ఇంతవరకు తెలియలేద్ు . 
అంద్ువలన ఈ విషయo గూరి  మేము ప్రిశోధించద్లిచనము. ఇంద్ు కొరకు , మీరప  మీ యొకక 10మిల్లు రకతము దననము 
చేయుట్కు మరియు మీ వ్ ైధుయనిచే సూచించే ఎండోస్ కప్ ప్రీక్ష చేయు సమయములో మీ చినా పరరగు ఫ ై భాగమునంద్ు ఒక 
చినా ముకకను ప్రిశోధనక ై తీసుకొనుట్కు మీ సమమతి తెలుప్గ్ోరపచున్నాము. మీరప ఇచేి రకతము మరియు పరరగు ముకక 
ఏదైెన్నను నమూన్న  మిగ్ిలితే అది భావిషయతులో ఇతర ప్రిశోధనలకు  ఉప్యోగ్ించబడును. 
మీ యొకక 10మిల్లు రకతము దననము చేయుట్ వలన మీకు ఏ విధమ ైన ఆరోగయ సమసయలు వుండవు .మీ యొకక వయకరతగత 
వివరాలన్నా అతయంత గ్ోప్యంగ్ా ఉంచ బడతనయి . 
మీ చినా పరరగు యొకక ముకక ప్రీక్ష దనవర మీకు ప్రతయక్షయముగ్ా ఎట్టవంటి్ ఉప్యోగం లేనప్ుటి్కద మద్యపానం చేయువ్ారిలో 
ఎకుకవ ఇనుము గిహియింప్బడి అది కాలేయములో చేరపతుంది అనా విషయానిా ప్రిశోధించుట్కు తోడుడుతుంది. 
ఇంద్ుకు అనగ్ా ప ైన పర కకనా ప్రీక్షలకు మేరకు అంగ్ీకారము లేని యెిడల మీరప నిరోమహమాట్ముగ్ా తెలుప్వచుిను 
ఇంద్ువలన ఆసుప్తిరలో మీకు ఇవవబడే చికరతయ యంద్ు ఎట్టవంటి్ మారపు వుండద్ు. 
మీకు ఏవిధమ ైన సందేహములు ఉనా ఎడల మీరప సంప్రదించ వలసి్టన చిరపన్నమ: 
డన . మధురవలిు , బయోక మిస్్టర ీడిపారపర మ ంట్ట,  సి్ట.ఎం.సి్ట, వ్ లలు రప. ఫ్ ను: 9566901857 
డన. ఏ. జ . జోస్ట ఫ్, పరర ఫ సర్, గస్ ్రర  ఎంటి్రాలజి డిపారపర మ ంట్ట,  సి్ట.ఎం.సి్ట, వ్ లలు రప. ఫ్ ను: 0416-2282496 
డన.ఈప న్ సి్ట.ఈ., పరర ఫ సర్, హెప్ట్ాలజీ డిపారపర మ ంట్ట,సి్ట.ఎం.సి్ట, వ్ లలు రప. ఫ్ ను: 0416-2283629 
డన, మోల్ల జాకబ్, పరర ఫ సర్, బయోక మిస్్టర  ీడిపారపర మ ంట్ట,  సి్ట.ఎం.సి్ట, వ్ లలు రప. ఫ్ ను:0416-2284267 
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CONSENT FORM FOR CONTROL PATIENTS (ENGLISH) 
Study Title: Duodenal HIF-2α and iron-related proteins in alcoholic liver disease 
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
The investigator has explained to me the details of the study proposed and what it involves. I 
have been asked to participate in this study for looking at how  iron is  handled in the body of 
patients with liver disease due to alcohol use and in patients who do not have this disease (as 
control patients). I understand that I am to be included as a control patient in this study. I have 
understood what has been said, including the following: 
1.  A very small sample of tissue from my gut will be taken by the doctor at the time of my 
endoscopy, which my treating doctor has advised me to have. 
2.  This will not create any additional difficulty for me when undergoing the procedure.  
3.  A sample of blood (10 ml) will also be collected from me. 
4.  Taking these samples will not affect my health in any foreseeable manner.  
5.  The samples will be used to study the processes by which iron is handled in patients who have 
liver disease due to alcohol intake. They will be used only for research purposes. Any sample or 
part of it that may remain at the end of the study will be stored and used for related research in 
the future.  
 
 I am willing to donate the tissue and blood samples voluntarily and without any coercion from 
the investigators of this project. 
 
 
 
Signature or thumb impression of the donor                                       Signature of the investigator 
 
 
 
Signature or thumb impression of the witness 
 
Name and address of the witness: 
 
 
Date: 
If you have any doubts or questions regarding the study, please contact one of the following:     
Dr.S.Mathuravalli, Department of Biochemistry, CMC, Vellore   Phone 9566901857    
Dr.A J Joseph, Professor and Head, Department of Gastroenterology CMC, Vellore Ph: 0416 
2282496 
Dr.Eapen CE, Professor and Head, Department of Hepatology CMC, Vellore Ph: 0416-2283629 
Dr.Molly Jacob, Professor and Head, Department of Biochemistry, CMC, Vellore Ph: 0416-
2284267 
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CONSENT FORM FOR ALD PATIENTS (ENGLISH) 
Study Title: Duodenal HIF-2α and iron-related proteins in alcoholic liver disease 
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
The investigator has explained to me the details of the study proposed and what it involves. I have 
understood what has been said, including the following: 
1. A very small sample of tissue from my gut will be taken by the doctor at the time of my 
endoscopic procedure, which my treating doctor has advised me to have. 
2.  It will not create any additional difficulty for me to undergo the procedure.  
3.  A sample of blood (10 ml) will also be collected from me. 
4.  Taking these samples will not affect my health in any foreseeable manner.  
5.  The samples will be used to study what happens to the processes by which iron is handled in 
patients who have liver disease due to alcohol intake. They will be used only for research 
purposes. Any sample or part of it that may remain at the end of the study will be stored and 
used for related research in the future.  
 I am willing to donate the tissue and blood samples and without any coercion from the investigators 
of this project. 
 
Signature /Thumb impression of the donor                                      Signature of the investigator 
 
Signature/ Thumb impression of the witness 
 
Name and address of the witness: 
Date: 
If you have any doubts or questions regarding the study, please contact one of the following:     
Dr.S.Mathuravalli, Department of Biochemistry, CMC, Vellore.   Phone 9566901857    
Dr.A J Joseph, Professor and Head, Department of Gastroenterology, CMC, Vellore. 
 Ph: 0416 2282496 
Dr.Eapen CE, Professor, Department of Hepatology, CMC, Vellore.  Ph: 0416-2283629 
Dr.Molly Jacob, Professor and Head, Department of Biochemistry, CMC, Vellore.  
Ph: 0416-2284267 
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CONSENT FORM FOR CONTROL PATIENTS (TAMIL) 
ஒப்புதல் படிவம்  (கல்லீரல் வ ோய் இல்ைோதேர்) 
 
மது சோர்ந்த கல்லீரல் வ ோய் உள்வ ோரின் குடல் ஹிப் 2 ஆல்ைோ மற்றும் இரும்பு   ிறைகள் 
 
ஆய்ேில் ைங்வகற்ைேரின் கையர் :திரு/திருமதி  
 
மருத்துேமறன அறடயோ  எண்         :                 ேயது                                  :  
 
இந்த ஆய்றே ைற்ைிய தகேல் ைடிேத்றத ைடித்தும் அதன் ேிேரங்கற   
மரு .மதுரேள் ி மூைம் வகட்டும் புரிந்து ககோண்வடன்] [.  
இந்த ஆய்வு கல்லீரல் வ ோய் உள்வ ோர் மற்றும் கல்லீரல் வ ோய் இல்ைோதேர் ஆகிய இரு ைிரிவுக ில் 
வமற்ககோள் ப்ைட உள் து  . ோன் கல்லீரல் வ ோய் இல்ைோதேர் ைிரிேில் ஆய்ேில் ைங்வகற்க 
சம்மதிக்கிவைன் ] [ . 
இந்த ஆய்ேில் கைந்து ககோள்  என்றன யோரும் கட்டோயப்ைடுத்தேில்றை  .எனது சுய  ேிருப்ைத்துடன் 
இந்த ஆய்ேில் ைங்வகற்கிவைன்  .வமலும் ,இந்த ஆய்ேிைிருந்து எந்வ ரமும் கோரைமின்ைி கே ிவயை 
எனக்கு அனுமதி உள் து.இதனோல் எனக்கு அ ிக்கப்ைடும் சிகிச்றச முறைக ில் எளேித வேறுைோடும் 
இருக்கோது என்று எனது மருத்துேர் உறுதி அ ித்துள் ோர்] [.  
இந்த ஆரோய்ச்சிக்கோக எனது சிறுகுடல் வமற்ைகுதி திசு மற்றும் 1௦ மில்ைி அ வு இரத்தம் ககோடுக்க முழு 
மனதுடன் சம்மதிக்கிவைன் . இதனோல் என் உடல்  ைத்திற்கு எந்தேித ைோதிப்பும் ஏற்ைடோது என அைிந்து 
ககோண்வடன்  .இந்த திசு மற்றும் இரத்தம் ஆரோய்ச்சிகோக மட்டுவம ையன்ைடுத்தப்ைடும் என ் று புரிந்து 
ககோண்வடன்] [ . 
மீதமோகும் இரத்தறத வசகரித்து ைின் ஆரோய்ச்சிக்கு ையன்ைடுத்த சம்மதிக்கிவைன் ] [ 
எனது மருத்துே ேிேரங்கற  ஆய்ேில் உைவயோகிக்க ஒப்புக்ககோள்கிவைன்  .இருப்ைினும் எனது தனிப்ைட்ட 
அறடயோ ம் /தகேல் ,மற்ைேரிடவமோ /மருத்துே இதபிவைோ கே ியிடப்ைட மோட்டோத ்  என்ைறதயும் 
கதரிந்து ககோண்வடன்] [. 
இந்த ஆய்ேின் முடிவு  /தகேறை அைிேியல் வ ோக்கத்திற்கு மட்டும் ையன்ைடுத்த  ோன் சம்மதிக்கிவைன்] [.  
இந்த ஆய்ேில் ைங்வகற்க முழுமனதுடன் சம்மதிக்கிவைன் ] [. 
 
ஆய்ேில் ைங்வகற்ைேரின் றககயோப்ைம் /கைருேிரல் வரறக                          :      வததி: 
 
முகேரி: 
 
 
சோட்சியின் கையர் மற்றும் முகேரி: 
 
 
வ ோயோ ிக்கு எந்த ேறகயில் கசோந்தம்: 
றககயோப்ைம் /கைருேிரல் வரறக                                     :ஆரோய்ச்சியோ ர் றககயோப்ைம்:  
 
இந்த ஆய்வு குைித்த சந்வதகங்கள் மற்றும் கதோடர்புக்கு கீழ்க்கண்ட  ைர்கற  அணுகவும்  
மரு மதுரேள் ி ,   உயிர் வேதியியல் துறை  ,வைோன் 9566901857  
மரு வ ோசப்  ,வைரோசிரியர் மற்றும் துறை தறைேர்  ,குடல் மற்றும் இறரப்றை துறை வைோன்    0416-2282496 
மரு ஈகைன் , வைரோசிரியர் மற்றும் துறை தறைேர்  ,கல்லீரல் வ ோயியல் துறை வைோன் 0416-2283629 
மரு வமோைி வ க்கப்  ,வைரோசிரியர் மற்றும் துறை தறைேர் ,உயிர் வேதியியல் துறை வைோன் 0416- 2284297 
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CONSENT FORM FOR ALD PATIENTS (TAMIL) 
ஒப்புதல் படிவம்  (மது சார்ந்த ேல்லீரல் க ாய் உள்க ார்) 
 
மது சோர்ந்த கல்லீரல் வ ோய் உள்வ ோரின் குடல் ஹிப் 2 ஆல்ைோ மற்றும் இரும்பு   ிறைகள் 
 
ஆய்ேில் ைங்வகற்ைேரின் கையர் :திரு/திருமதி  
 
மருத்துேமறன அறடயோ  எண்                          :ேயது        :                           
 
இந்த ஆய்றே ைற்ைிய தகேல் ைடிேத்றத ைடித்தும் அதன் ேிேரங்கற   
மரு .மதுரேள் ி மூைம் வகட்டும் புரிந்து ககோண்வடன்] [. 
இந்த ஆய்ேில் கைந்து ககோள்  என்றன யோரும் கட்டோயப்ைடுத்தேில்றை  .எனது சுய ேிருப்ைத்துடன் 
இந்த ஆய்ேில் ைங்வகற்கிவைன் .வமலும் ,இந்த ஆய்ேிைிருந்து எந்வ ரமும் கோரைமின்ைி கே ிவயை 
எனக்கு அனுமதி உள் து.இதனோல் எனக்கு அ ிக்கப்ைடும் சிகிச்றச முறைக ில் எளேித வேறுைோடும் 
இருக்கோது என்று எனது மருத்துேர் உறுதி அ ித்துள் ோர்] [. 
இந்த ஆரோய்ச்சிக்கோக எனது சிறுகுடல் வமற்ைகுதி திசு மற்றும் 1௦ மில்ைி அ வு இரத்தம் ககோடுக்க முழு 
மனதுடன் சம்மதிக்கிவைன் . இதனோல் என் உடல்  ைத்திற்கு எந்தேித ைோதிப்பும் ஏற்ைடோது என அைிந்து 
ககோண்வடன்  .இந்த திசு மற்றும் இரத்தம் ஆரோய்ச்சிகோக மட்டுவம ையன்ைடுத்தப்ைடும் என்று புரிந்து 
ககோண்வடன்] [ .  
மீதமோகும் இரத்தறத வசகரித்து ைின் ஆரோய்ச்சிக்கு ையன்ைடுத்த சம்மதிக்கிவைன் ] [ 
எனது மருத்துே ேிேரங்கற  ஆய்ேில் உைவயோகிக்க ஒப்புக்ககோள்கிவைன்  .இருப்ைினும் எனது தன ்ிப்ைட்ட 
அறடயோ ம்  /தகேல் ,மற்ைேரிடவமோ /மருத்துே இதபிவைோ கே ியிடப்ைட மோட்டோது என்ைறதயும் 
கதரிந்து ககோண்வடன்] [.  
இந்த ஆய்ேின் முடிவு  /தகேறை அைிேியல் வ ோக்கத்திற்கு மட்டும் ையன்ைடுத்த  ோன் சம்மதிக்கிவைன்] [.  
இந்த ஆய்ேில் ைங்வகற்க முழுமனதுடன் சம்மதிக்கிவைன் ] [. 
 
ஆய்ேில் ைங்வகற்ைேரின் றககயோப்ைம் /கைருேிரல் வரறக                               :வததி:  
 
முகேரி: 
 
 
சோட்சியின் கையர் மற்றும் முகேரி: 
 
 
வ ோயோ ிக்கு எந்த ேறகயில் கசோந்தம்: 
றககயோப்ைம் /கைருேிரல் வரறக                                     :ஆரோய்ச்சியோ ர் றககயோப்ைம்:  
 
இந்த ஆய்வு குைித்த சந்வதகங்கள் மற்றும் கதோடர்புக்கு கீழ்க்கண்ட  ைர்கற  அணுகவும்  
மரு மதுரேள் ி   உயிர் வேதியியல் துறை வைோன் 9566901857  
மரு வமோைி வ க்கப் உயிர் வேதியியல் துறை வைோன் 0416- 2284297 
மரு வ ோசப் குடல் மற்றும் இறரப்றை துறை வைோன்   0416-2282496 
மரு ஈகைன் கல்லீரல் வ ோயியல் துறை வைோன் 0416-2283629 
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CONSENT FORM FOR CONTROLS (HINDI) 
सूधचत सहमनत फॉमत : ननयंत्रण रोधगयों के लिए। 
अध््यन शीर्तक: शराब के सेवन से जिगर सम्बंधधत बीमारी में ग्रहणी एच. आई. एफ. २ आल्फा 
और िोहे से संबंधधत प्रोटीन की मात्रा। 
प्रनतभागी का नाम: 
िन्म नतधि / उम्र:  
डॉक्टर के द्वारा मुझ ेप्रस्ताववत अध्ययन का वववरण ववस्तार से बताया गया है। मुझ ेएक 
अध््यन में भाग िेने का कहा गया है जिसमे शरीर में होने वािे िोहे के ननयंत्रत्रत में पररवततन 
को िांचा िाएगा, ऐसे रोधगयों  में जिन्हें शराब के सेवन से जिगर सम्बंधधत बीमारी है और 
उनमें जिन्हें बीमारी नहीं है। मुझ ेननम्नलिखखत सहहत, क्या कहा गया है समझ में आ गया है : 
 
1. मेरे पेट से ऊतक का एक बहुत छोटा सा नमूना इंडोस्कोवपक प्रकिया के समय 
धचककत्सक द्वारा लिया िाएगा, जिसकी सिाह मेरा इिाि करते धचककत्सक ने मुझ ेदी है। 
2. यह प्रकिया के दौरान मेरे लिए कोई अनतररक्त कहिनाई पैदा नहीं करेगी। 
3. एक रक्त का नमूना (१० लमिीिीटर) भी मुझसे एकत्र ककया िाएगा। 
4. यह नमूने देने से मेरा स्वास््य ककसी भी ज्ञात रूप से  प्रभाववत नहीं होगा। 
5. लिए गए नमूने यह अध्ययन करने के लिए इस्तमाि ककये िाएंगे कक शराब का सेवन 
करने से हुई जिगर की त्रबमारी से पीहित रोधगयों में िोहे का ननयंत्रण कैसे होता है। लिए गए 
नमूने केवि शोध उदे्दचयों के लिए ही इस्तेमाि ककए िाएंगे। 
मैं स्वेच्छा, त्रबना िांचकतातओं के ओर से ककसी भी प्रकार के दबाव में आकर, इस अध्ययन में 
भाग िेने के लिए और वसा ऊतकों के नमूनों और रक्त का १० लमिीिीटर दान करने के लिए 
सहमती देता हूाँ। 
प्रनतभागी के हस्ताक्षर/ अगंूिे का ननशान                            अन्वेर्क के हस्ताक्षर 
साक्षी  के हस्ताक्षर/ अगंूिे का ननशान 
साक्षी का नाम और पता                                              
नतधि: 
अगर आपको अध्ययन के बारे में कोई संदेह या प्रचन हैं, तो ननम्न में से एक से संपकत  करें: 
1. डॉ एस. मधरुवजल्ि, िैव रसायन ववभाग, सी एम सी , वेल्िोर, फोन 9566901857 
2. डॉ ए.िे. िोसेफ , प्रोफेसर और हेड, गैस्रोएंटरोिॉिी ववभाग , सी एम सी , वेल्िोर । फोन: 
0416 2282496 
3. डॉ ऐपन सी. ई., प्रोफेसर, हेप्टोिोिी ववभाग, सी एम सी , वेल्िोर । फोन: 0416-2283629 
4. डॉ मौिी िेकोब, प्रोफेसर और हेड, िैव रसायन ववभाग, सी एम सी, वेल्िोर । फोन: 0416-
2284267 
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शराब के सेवन से जिगर सम्बधंधत बीमारी से पीहित रोधगयों के लिए। 
अध््यन शीर्तक: शराब के सेवन से जिगर सम्बधंधत बीमारी में ग्रहणी एच. आई. एफ. २ आल्फा और 
िोहे से सबंधंधत प्रोटीन की मात्रा। 
प्रनतभागी का नाम: 
िन्म नतधि / उम्र:  
डॉक्टर के द्वारा मझुे प्रस्ताववत अध्ययन का वववरण ववस्तार से बताया गया है। मझुे ननम्नलिखखत 
सहहत, क्या कहा गया है समझ में आ गया है : 
1. मेरे पेट से ऊतक का एक बहुत छोटा सा नमनूा इंडोस्कोवपक प्रकिया के समय धचककत्सक द्वारा 
लिया िाएगा, जिसकी सिाह मेरा इिाि करत ेधचककत्सक ने मझुे दी है। 
2. यह प्रकिया के दौरान मेरे लिए कोई अनतररक्त कहिनाई पदैा नहीं करेगी। 
3. एक रक्त का नमनूा (१० लमिीिीटर) भी मझुसे एकत्र ककया िाएगा। 
4. यह नमनेू देने से मेरा स्वास््य ककसी भी ज्ञात रूप स े प्रभाववत नहीं होगा। 
5. लिए गए नमनेू यह अध्ययन करने के लिए इस्तमाि ककये िाएंगे कक शराब का सेवन करने से 
हुई जिगर की त्रबमारी से पीहित रोधगयों में िोहे का ननयतं्रण कैसे होता है। लिए गए नमनेू केवि शोध 
उद्देचयों के लिए ही इस्तमेाि ककए िाएगंे। 
मैं स्वेच्छा, त्रबना िांचकतातओं के ओर से ककसी भी प्रकार के दबाव में आकर, इस अध्ययन में भाग िेने 
के लिए और वसा ऊतकों के नमनूों और रक्त का १० लमिीिीटर दान करने के लिए सहमती देता हूाँ। 
 
 
 
प्रनतभागी के हस्ताक्षर/ अगंिेू का ननशान                            अन्वेर्क के हस्ताक्षर 
 
साक्षी  के हस्ताक्षर/ अगंिेू का ननशान 
 
साक्षी का नाम और पता                                              
 
नतधि: 
 
 
अगर आपको अध्ययन के बारे में कोई सदेंह या प्रचन हैं, तो ननम्न में से एक स ेसपंकत  करें: 
1. डॉ एस. मधुरवजल्ि, िैव रसायन ववभाग, सी एम सी , वेल्िोर, फोन 9566901857 
2. डॉ ए.िे. िोसेफ , प्रोफेसर और हेड, गसै्रोएंटरोिॉिी ववभाग , सी एम सी , वेल्िोर । फोन: 0416 
2282496 
3. डॉ ऐपन सी. ई., प्रोफेसर, हेप्टोिोिी ववभाग, सी एम सी , वेल्िोर । फोन: 0416-2283629 
4. डॉ मौिी िेकोब, प्रोफेसर और हेड, िैव रसायन ववभाग, सी एम सी , वेल्िोर । फोन: 0416-
2284267 
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రక్త నమూన మరియు చినన ప్రగు నమూన సరక్రణన సమాచార పతే్ము  
ప్రిశోధన అంశం :    తనర గుడు వలన కలుగు లివర్ వ్ాయధిలో HIF 2α మరియు ఐరన్ మరియు చినా పరగు సంబంధిత  ఆమాు లు    
గురించి . 
వయకరత పర ప                    :  
వయసు , ప్ుట్ిరన తేది  : 
     
                        ఈ ప్రిశోధన వయకరత న్నకు ప్ూరిాగ్ా  వివరించనరప , అంద్ులోని అంశాలను కలడన తెలియచేసారప. ఈ ప్రిశోధనకు 
ననుా ఇనుము శకదత ఏ విధంగ్ా కాలేయ వ్ాయధ ిగిసుత లకు ప్ని చసేుత ంద ిఅని ప్రయోగము చేసాత మని తలెియజసే్టిన్నరప. 
న్నకు కాలేయ వ్ాయధి లేనంద్ున ననుా ఒక కంట్రర లు పరషరనుర గ్ా (వ్ాయధి లేనివ్ారప అని అరధం ) వయవహరిసాత రప .  న్నకు 
ప్ూరిాగ్ా అరామయింది అలాగ్ే కరంద్ విషయాలను కలడన తెలుసుకున్నాను : 
 
1. చినా పరగు యొకక నమూన న్న శరీరం నుండి కొంత ప్రిశోధన కొరక ై ఎండో స్ కప్ సమయంలో స్టరకరించబడుతుంది, అది ననుా 
ప్రీక్ించే డనకర ప గ్ారిచే వివరించడమ ైనది.  
2. ఈ ప్రీక్ా సమయంలో న్నకు ఏ ఇబబంది కలుగద్ు.  
3. 10 మి.ల్ల. రకతము కలడన స్టరకరించబడుతుంది .  
4. ఈ నమూన్నలను స్టరకరించుట్వలన న్నకు ఏ ఇతర ఇబబంది ఏ విధంగ్ా అయినను కలుగద్ు.  
5. నమూన్నలను కేవలము ప్రిశోధన కొరక ై వ్ాడుతనరప, తనర గుడు వలన వచేి లివరప  వ్ాయధి ఉనా వయకరతలో ఇనుము ఎలా 
మారపతుందో  అనే్ అంశం కొరకు . ఇక ఏదైెన్న నమూన  మిగ్ిలితే అది భవిశయతుత లో కేవలము ప్రిశోధనక ై  వ్ాడబడుతుంది .  
 
నే్ను మనసూురితగ్ా నమున్నలను స్టరకరించుట్కు అంగ్ికరిసుత న్నాను, మరియు న్నకుప్రిశోధకుల దనవరా  ఏ ఇతర ఆట్ంకము లేద్ని 
గురితంచన.   
 
దనత యొకక సంతకం / వే్లిముద్ర                                                             ప్రిశోద్కుని యొకక సంతకం / వే్లిముద్ర  
 
సాక్ి సంతకం / వే్లిముద్ర  
 
సాక్ి పర ప మరియు అడరసుయ : 
 
తేది: 
 
మీకు ఏవిధమ ైన సందేహములు ఉనా ఎడల మీరప సంప్రదంిచ వలస్టని చిరపన్నమ: 
డన . మధురవలిు, బయోక మిస్ట్ర  ీడిపారపర మ ంట్ట,  స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను: 9566901857 
డన. ఏ. జ . జోస్ట ఫ్, పర ర ఫ సర్, గస్ ్రర  ఎంట్ిరాలజి డిపారపర మ ంట్ట,  స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను: 0416-2282496 
డన.ఈప న్ స్టి.ఈ., పర ర ఫ సర్, హెప్ట్ాలజీ డిపారపర మ ంట్ట,స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను: 0416-2283629 
డన, మోల్ల జాకబ్, పర ర ఫ సర్, బయోక మిస్ట్ర  ీడిపారపర మ ంట్ట,  స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను:0416-2284267 
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    రక్త నమూన మరియు చినన ప్రగు నమూన సరక్రణన సమాచార పతే్ము  
 
ప్రిశోధన అంశం :    తనర గుడు వలన కలుగు లివర్ వ్ాయధిలో HIF 2α మరియు ఐరన్ మరియు చినా పరగు సంబంధిత  ఆమాు లు    
గురించి . 
 
 వయకరత పర ప                    :  
వయసు , ప్ుట్ిరన తేది  : 
     
                        ఈ ప్రిశోధన వయకరత న్నకు ప్ూరిాగ్ా  వివరించనరప , అంద్ులోని అంశాలను కలడన తెలియచేసారప. న్నకు ప్ూరిాగ్ా 
అరామయింది అలాగ్ే కరంద్ విషయాలను కలడన తెలుసుకున్నాను : 
 
1. చినా పరగు యొకక నమూన న్న శరీరం నుండి కొంత ప్రిశోధన కొరక ై ఎండో స్ కప్ సమయంలో స్టరకరించబడుతుంది, అది ననుా 
ప్రీక్ించే డనకర ప గ్ారిచే వివరించడమ ైనద్.  
2. ఈ ప్రీక్ా సమయంలో న్నకు ఏ ఇబబంది కలుగద్ు.  
3. 10 మి.ల్ల. రకతము కలడన స్టరకరించబడుతుంది .  
4. ఈ నమూన్నలను స్టరకరించుట్వలన న్నకు ఏ ఇతర ఇబబంది ఏ విధంగ్ా అయినను కలుగద్ు.  
5. నమూన్నలను కేవలము ప్రిశోధన కొరక ై వ్ాడుతనరప, తనర గుడు వలన వచేి లివరప వ్ యాధి ఉనా వయకరతలో ఇనుము ఎలా 
మారపతుందో  అనే్ అంశం కొరకు. ఇక ఏదైెన్న నమూన  మిగ్ిలితే అది భవిశయతుత లో కేవలము ప్రిశోధనక ై  వ్ాడబడుతుంది .  
 
నే్ను మనసూురితగ్ా నమున్నలను స్టరకరించుట్కు అంగ్ికరిసుత న్నాను, మరియు న్నకుప్రిశోధకుల దనవరా  ఏ ఇతర ఆట్ంకము లేద్ని 
గురితంచన.   
 
 
దనత యొకక సంతకం / వే్లిముద్ర                                                             ప్రిశోద్కుని యొకక సంతకం / వే్లిముద్ర  
 
సాక్ి సంతకం / వే్లిముద్ర  
 
సాక్ి పర ప మరియు అడరసుయ : 
 
తేది: 
మీకు ఏవిధమ నై సందహేములు ఉనా ఎడల మీరప సంప్రదించ వలస్టని చిరపన్నమ: 
డన . మధురవలిు, బయోక మిస్ట్ర  ీడిపారపర మ ంట్ట,  స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను: 9566901857 
డన. ఏ. జ . జోస్ట ఫ్, పర ర ఫ సర్, గస్ ్రర  ఎంట్రిాలజి డిపారపర మ ంట్ట,  స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను: 0416-2282496 
డన.ఈప న్ స్ట.ిఈ., పర ర ఫ సర్, హెప్ట్ాలజీ డిపారపర మ ంట్ట,స్టి.ఎం.స్ట,ి వ్ లలు రప. ఫ్ ను: 0416-2283629 
డన, మోల్ల జాకబ్, పర ర ఫ సర్, బయోక మిస్ట్ర  ీడిపారపర మ ంట్ట,  స్ట.ిఎం.స్ట,ి వ్ లలు రప. ఫ్ ను:0416-2284267 
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APPENDIX III: PATIENT PROFORMA 
 
Departments of Biochemistry, Gastroenterology and Hepatology, 
Christian Medical College, Vellore- 632002 
 
Duodenal HIF-2α and iron transporters in alcoholic liver disease 
Details collected by:                                                                                      Date    :     
                                                                                                       
Name  
 
Age  
Sex  
 
Hospital No 
Address  
 
 
 
 
 
Phone No 
 
1. Personal history:  
Diet:  Veg / non-veg              
Alcohol use: yes/ no. If yes, no. of years-                                                                      
Smoking: yes/ no. If yes, no. of years- 
 
2. Medical history: 
 H/O diabetes: yes/no. If yes, no. of years- 
 H/O hypertension: yes/no. If yes, no. of years- 
 Any other illness: 
 
3. Treatment history: Any drug intake, any treatment in the past 
 
4. Final diagnosis: 
 
5. Laboratory investigations: 
Hemoglobin: TIBC Transferrin saturation 
Serum iron: Serum ferritin LFT 
 
6. Endoscopy report:  
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APPENDIX IV: MIQE CHECKLIST FOR qPCR 
 
Item to check Importance* 
 
Response 
EXPERIMENTAL 
DESIGN 
 
  
Definition of experimental 
and control groups 
E 
 
Duodenal mucosal samples obtained from 
ALD patients and control patients were used 
for all experiments. 
 
Number within each group E In all experiments, 18 mucosal samples from 
controls and 17 mucosal samples from ALD 
patients were used.  
 
Assay carried out by core lab 
or investigator's lab? 
D 
 
Assays were carried out in the investigators’ 
lab 
 
 
SAMPLE 
 
  
Description E Duodenal mucosal sample obtained from D2 
segment 
 
Volume/mass of sample 
processed 
 
D 
 
Small bit of duodenal mucosal sample 
Micro dissection or macro 
dissection 
 
E 
 
Not applicable 
Processing procedure E 0.5 mL of TRI-reagent was added to one 
microtube and one plain microtube was used 
for collecting the mucosal samples  
. 
If frozen - how and how 
quickly? 
E 
 
Mucosal samples in plain tube were snap 
frozen in liquid nitrogen immediately and 
both the tubes were transferred to a -70°C 
freezer 
 
If fixed - with what, how 
quickly? 
 
E 
 
Not applicable 
Sample storage conditions and 
duration (especially for FFPE 
samples) 
 
E 
 
Samples were stored at - 70°C until processed 
for homogenization and RNA isolation 
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NUCLEIC ACID 
EXTRACTION 
 
  
 
Procedure and/or 
instrumentation 
 
E 
 
 
Guanidinium thiocyanate-phenol-chloroform 
extraction method using TRI-reagent (Sigma) 
 
Name of kit and details of any 
modifications 
 
E 
 
Not applicable 
Source of additional reagents 
used 
D 
 
Chloroform and isopropanol used for RNA 
isolation were of molecular biology grade 
obtained from Sigma. 
 
Details of DNase or RNAse 
treatment 
 
E 
 
Not done 
Contamination assessment 
(DNA or RNA) 
E 
 
All samples were run on 1% agarose gel to 
look for DNA contamination and RNA 
integrity. 
 
Nucleic acid quantification E Done using a nanospectrophotometer 
 
Instrument and method E NanoDrop2000c from Thermo Fischer 
 
Purity (A260/A280) D A260/A280 for all samples were > 1.80 
 
RNA integrity 
method/instrument 
E 
 
All samples were run on a 1% agarose gel. 
Only those samples that showed clear and 
distinct bands corresponding to 18s and 28s 
rRNA were used for cDNA construction 
 
RIN/RQI or Cq of 3' and 5' 
transcripts 
 
E 
 
Not done 
 
REVERSE 
TRANSCRIPTION 
 
  
Complete reaction conditions E For 1 reaction, 5х Prime script buffer          
2μL, RT enzyme mix with RNase inhibitor 
0.5 μL, Oligo dT primer 0.5 μL (final 
concentration 25pmol),Random 6mers                     
0.5 μL (final concentration 50pmol) 
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Amount of RNA and reaction 
volume 
E 
 
500ng of total RNA was added to make a total 
volume of 10µL with DEPC water 
 
Priming oligonucleotide (if 
using GSP) and concentration 
 
E 
 
Not applicable 
Reverse transcriptase and 
concentration 
E 
 
PrimeScript™ RT enzyme mix  
(Concentration not specified by the kit 
manufacturer) 
Temperature and time E 37
0
C for 15 minutes, 85
0
C for 5seconds, 4
0 
C 
for 10 minutes 
 
Manufacturer of reagents and 
catalogue numbers 
D 
 
PrimeScript™ RT Reagent Kit (Perfect Real 
Time) TaKaRa Clontech  
Catalog number RR037A 
 
Storage conditions of cDNA D -20°C 
 
qPCR TARGET 
INFORMATION 
 
  
If multiplex, efficiency and 
LOD of each assay 
E Not applicable 
Sequence accession number D Information provided in qPCR standardization 
data table (Methods) 
 
Amplicon length E Information provided in qPCR standardization 
data table (Methods)  
 
In silico specificity screen 
(BLAST, etc) 
E 
 
Primer BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) was used to check the specificity of 
each primer-pair used. 
Pseudogenes, 
retropseudogenes or other 
homologs? 
 
D 
 
No 
Location of each primer by 
exon or intron (if applicable) 
 
E Not applicable 
What splice variants are 
targeted? 
 
 
 
E 
 
Primers were designed to amplify all splice 
variants of the target genes 
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qPCR 
OLIGONUCLEOTIDES 
 
  
Primer sequences E Information provided in primer sequence table 
(Methods) 
 
RTPrimerDB Identification 
Number 
D 
 
Not applicable 
Probe sequences D Not applicable 
 
Location and identity of any 
modifications 
E 
 
Not applicable 
Manufacturer of 
oligonucleotides 
D 
 
Beta- actin: Sigma, India 
DMT-1, FPN, Dcytb:  Eurogentec, Belgium 
 
 
qPCR PROTOCOL 
 
  
 
Reaction volume and amount 
of cDNA/DNA 
E 
 
10 µL reaction volume containing 2 µL 
cDNA diluted 1:10 
 
Primer, (probe), Mg++ and 
dNTP concentrations 
E 
 
Final concentrations were: 
Primer: 250nM 
Mg
2+
 : 2.5mM 
dNTPs: not specified by the kit manufacturer 
 
Polymerase identity and 
concentration 
 
 
E 
 
TaKaRa Ex Taq HS DNA Polymerase 
(concentration not specified by the kit 
manufacturer) 
 
Buffer/kit identity and 
manufacturer 
E 
 
SYBR® Premix Ex Taq™ II (Tli RNaseH 
Plus)Cat # RR820A 
 
Exact chemical constitution of 
the buffer 
D 
 
Information not provided by the kit 
manufacturer 
 
Additives (SYBR Green I, 
DMSO, etc.)  
E Not applicable 
Manufacturer of plates/tubes 
and catalog number 
D 
 
96-well plates from Axygen Scientific 
(catalogue number: PCR-96-FS-C) 
 
Complete thermocycling 
parameters 
E 
 
95°C for 5 min, followed by 40 cycles of 
95°C for 10 sec and 60°C for 60 sec 
 
Reaction setup 
(manual/robotic) 
D 
 
Manual 
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Manufacturer of qPCR 
instrument 
 
E 
 
BioRad Chromo4 real-time PCR machine 
qPCR VALIDATION 
 
  
Specificity (gel, sequence, 
melt, or digest) 
E 
 
Melt curve analysis was done for all PCR runs 
for all the genes. Single peaks were detected. 
No primer dimers were seen in any of reaction 
wells. 
 
For SYBR Green I, Cq of the 
NTC 
E Information provided in the qPCR validation 
data table (Methods) 
  
Standard curves with slope 
and y-intercept 
E 
 
Information provided in the qPCR validation 
data table (Methods) 
 
PCR efficiency calculated 
from slope 
E 
 
Information provided in the qPCR validation 
data table (Methods) 
 
r
2
 of standard curve E Information provided in the qPCR validation 
data table (Methods) 
 
 
Linear dynamic range E Information provided in qPCR validation data 
table (Methods) 
 
 
Cq variation at lower limit E Not applicable 
 
If multiplex, efficiency and 
LOD of each assay. 
E 
 
Not applicable 
 
DATA ANALYSIS 
 
  
qPCR analysis program 
(source, version) 
E 
 
MJ Opticon Monitor Analysis Software 
Version 3.1 (BioRad) 
 
Cq method determination E Manual 
 
Outlier identification and 
disposition 
 
E 
 
Not applicable 
Results of NTCs       E Information provided in the qPCR validation 
data table (Methods) 
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Justification of number and 
choice of reference genes 
E The reference gene used was beta-actin. The 
choice was based on previous publications 
which have used beta actin as the reference 
gene. 
 
Description of normalisation 
method 
 
E 
 
The ΔΔCt method was used for normalization 
 
Number and stage (RT or 
qPCR) of technical replicates 
E All reactions were conducted in 
quadruplicates when qPCR was carried out. 
Repeatability (intra-assay 
variation) 
E 
 
Average of Cq values for quadruplicates was 
taken for calculation.  
 
Statistical methods for result 
significance 
E 
 
Mann Whitney test was used for all 
comparisons. 
 
Software (source, version) E SPSS version 16.0 
 
 
* E – essential, D - desirable 
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APPENDIX V: MASTER DATA SHEET  
 
 
Controls  Age  Sex Hb INR Glucose  Creatinine MCV WBC 
count  
hs-
CRP 
1 50 M 12.3 0.95 Ran-95 0.91 69 5100 0.407 
2 55 M 13.8  AC 95 0.83 83.9 8900 0.921 
3 42 M 15.1 0.95 AC-101 0.73 80.7 6500 7.71 
4 43 M 14.3      3.09 
5 45 M 14.9 0.94 PC 116 0.69 99.8 7100 0.242 
6 40 M 11.4 1 AC 81 0.75 77.7 3700 1.16 
7 41 M 14.9 1.05 PC 93 1.14 77.2 5200 0.429 
8 52 M 14.5  PC 335 1.02 87.8 7900 2.26 
9 61 M 15.1  PC 173 0.85 85.4 7900 1.97 
10 54 M 13.7 0.95 PC 105 1.09 82.1 9400 2.71 
11 51 M 13.8  PC 109 0.91 75.9 9800 0.546 
12 39 M 14.6  PC 173 1.12 86.4 10000 6.82 
13 42 M 13.2   1.04 73.2  0.487 
14 59 M 12.5  PC  208 0.74 83.3 9000 0.97 
15 38 M 15.5  PC 104 1.06   0.39 
16 57 M 16.8   0.98   1.11 
17 54 M 15.2   0.79 77.7 7800 0.243 
18 47 M 15   0.68   0.442 
Cases          
1 48 M 7.7 1.31  0.7 85.6 4900 9.81 
2 46 M 10.6 1.43  0.75 83.9 6400 7.74 
3 43 M 12 1.27 pc- 117 1.12 98 7500 7.27 
4 48 M 8.2 1.05 pc-121 1.63 100.6 4100 0.904 
5 40 M 19.2 1.05   96.6 9500 3.33 
6 66 M 13.4 0.95 pc 181 0.84 89.5 11300 1.38 
7 53 M 12.8 1.34 pc 115 1.28 105.4 4700 4.58 
8 51 M 11.2 1.26 pc 139 0.75 77.8 8000 29.4 
9 42 M 11.9 1.3 ran 80 0.68 91 11000 71.6 
10 38 M 10.3 1.5 AC 118 0.51 96.5 4500 6.25 
11 49 M 11.1 1.04  1.06 91.5 8200 5.44 
12 47 M 10.9 1.36 pc 177 0.93 81.3 8400 15.15 
13 46 M 13.7 0.98 pc 511 0.9 69.4 7600 4.2 
14 57 M 9.2 1.46 ran 147 1.08 106.9 16800 10.2 
15 46 M 11.8 1.49 pc 196 0.66 93.5 7300 4.49 
16 45 M 10.1 1.48 ran 99 0.84 87.8 3900 0.681 
17 58 M 10.4 1.33  0.64 94.9 8900 3.43 
18 38 M 13.6  pc 105 1.04 79.9 7600 6.24 
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Controls  T.bilirubin D.bilirubin T.protein Albumin 
A:G 
ratio AST 
          
ALT      ALP 
1 0.8 0.2 7.6 4.7 1.62 18 19 22 
2 0.3 0.16 7.3 4.6 1.70 19 16.3 68 
3 0.5 0.2 7.4 4.3 1.39 29 45 69 
4 0.32 0.07 7.2 4.5 1.67 29 30.5 83 
5 0.4 0.2 7 4.5 1.80 47 63 92 
6 0.5 0.2 7.8 3 0.63 72 38 95 
7 0.3 0.2 7.4 4.6 1.64 21 20 56 
8 0.7 0.2 7.2 4.7 1.88 15 28 71 
9 0.6 0.1 7.5 4.6 1.59 23 23 31 
10 0.9 0.3 7.4 4.3 1.39 24 22 68 
11 0.6 0.3 7.9 5.1 1.82 21 30 94 
12 0.4 0.1 7.9 4.5 1.32 19 17 74 
13 0.4 0.2 7.4 4.3 1.39 24 36 81 
14 0.2 0.1 7.6 5 1.92 14 14 81 
15 0.5 0.2 7.7 4.7 1.57 25 36 92 
16 1 0.3 7.6 4.3 1.30 32 27 73 
17 1.1 0.2 7.5 4.6 1.59 25 25 72 
18 1.1 0.4 7.5 4.6 1.59 30 24 65 
Cases 
        1 3.3 1.4 7.6 3.3 0.77 32 13 97 
2 3.7 2 8.1 2.7 0.50 91 32 102 
3 3.5 1.5 7.7 3.4 0.79 91 46 110 
4 1 0.3 7.5 3.5 0.88 29 19 94 
5 1.3 0.2 6.7 4.3 1.79 26 33 64 
6 0.7 0.2 7.1 4 1.29 163 57 86 
7 7 3.4 7.5 3.1 0.70 95 32 119 
8 10.4 5.7 6.8 3.4 1.00 75 30 175 
9 15 14.1 7 2.8 0.67 209 108 540 
10 4.5 2.8 7.8 2.5 0.47 82 6 179 
11 2.2 2 7.6 4.1 1.17 169 116 84 
12 3.6 2.9 8 2.6 0.48 64 34 127 
13 0.4 0.2 8 4.6 1.35 44 70 82 
14 16 13.2 6.2 2.5 0.68 69 54 118 
15 1.5 0.7 8.9 2.7 0.44 242 59 121 
16 2.5 1.9 7.4 2.9 0.64 23 7 111 
17 5.1 3 8.3 2.4 0.41 73 25 155 
18 2.5 0.7 7.7 4.7 1.57 38 48 61 
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Controls  S.iron TIBC Tf sat Ferritin  DMT-1 FPN DCYTB HIF 2α 
1 26 310 8.39 55 0.16 0.25 0.86 
 2 44 319 13.79 190 0.81 1.00 0.86 0.13 
3 27 347 7.78 45 0.17 0.09 0.32 
 4 91 375 24.27 64 0.34 0.36 0.57 0.10 
5 107 331 32.33 68 1.82 1.59 1.97 0.23 
6 47 238 19.75 505 0.83 0.84 0.71 0.04 
7 119 315 37.78 17.1 4.77 4.11 1.88 0.05 
8 83 298 27.85 117 0.71 1.07 1.14 
 9 108 345 31.30 68.1 1.33 1.54 1.75 0.26 
10 62 416 14.90 9.7 4.84 3.47 1.64 0.06 
11 74 367 20.16 55.2 0.69 1.18 0.81 0.03 
12 72 275 26.18 519 1.49 0.99 0.75 0.04 
13 82 312 26.28 108 2.64 2.10 0.95 
 14 79 413 19.13 8.9 1.75 3.42 2.13 0.03 
15 130 288 45.14 169 0.57 0.17 0.45 
 16 106 286 37.06 80 0.35 1.52 1.19 0.05 
17 90 364 24.73 21.7 2.62 0.67 0.91 0.02 
18 54 424 12.74 16.3 2.13 1.24 0.52 0.01 
Cases 
        1 48 413 11.62 27.5 5.098 3.095 0.753 0.020 
2 87 185 47.03 28.6 2.789 2.770 0.688 0.030 
3 102 251 40.64 418.5 1.050 1.275 0.563 0.030 
4 114 302 37.75 154.8 6.277 2.173 0.883 
 5 230 251 91.63 541 0.183 0.423 0.796 0.140 
6 96 357 26.89 66.5 3.340 1.102 0.540 0.050 
7 155 194 79.90 380.8 0.946 1.240 0.582 0.220 
8 30 154 19.48 759.8 0.423 0.669 0.507 0.040 
9 42 177 23.73 1667 0.599 1.050 1.181 0.240 
10 146 179 81.56 1261.7 1.301 0.559 0.426 0.240 
11 74 238 31.09 938 
    12 122 182 67.03 174.4 1.275 1.945 1.347 0.030 
13 52 344 15.12 378 0.956 2.274 1.434 0.030 
14 157 160 98.13 4972 0.206 0.480 1.117 0.010 
15 52 189 27.51 153.3 4.757 2.403 1.181 0.040 
16 55 349 15.76 22 2.809 3.283 0.629 0.170 
17 118 274 43.07 3.29 0.332 0.763 0.559 0.010 
18 53 292 18.15 415 3.204 1.347 0.768 
  
